University of Wisconsin Milwaukee

UWM Digital Commons
Theses and Dissertations

August 2016

Development of a Systemic Lupus Erythematosus
Knowledge Questionnaire: The Relationship
Among Disease Proximity, Educational Exposure
and Knowledge
Shelbie Sullivan
University of Wisconsin-Milwaukee

Follow this and additional works at: https://dc.uwm.edu/etd
Part of the Psychology Commons
Recommended Citation
Sullivan, Shelbie, "Development of a Systemic Lupus Erythematosus Knowledge Questionnaire: The Relationship Among Disease
Proximity, Educational Exposure and Knowledge" (2016). Theses and Dissertations. 1312.
https://dc.uwm.edu/etd/1312

This Thesis is brought to you for free and open access by UWM Digital Commons. It has been accepted for inclusion in Theses and Dissertations by an
authorized administrator of UWM Digital Commons. For more information, please contact open-access@uwm.edu.

DEVELOPMENT OF A SYSTEMIC LUPUS ERYTHEMATOSUS KNOWLEDGE
QUESTIONNAIRE: THE RELATIONSHIP AMONG DISEASE PROXIMITY,
EDUCATIONAL EXPOSURE, AND KNOWLEDGE

by
Shelbie Lee Sullivan

A Thesis Submitted in
Partial Fulfillment of the
Requirements for the Degree of

Master of Science
in Psychology

at
The University of Wisconsin-Milwaukee
August 2016

ABSTRACT
DEVELOPMENT OF A SYSTEMIC LUPUS ERYTHEMATOSUS KNOWLEDGE
QUESTIONNAIRE: THE RELATIONSHIP AMONG DISEASE PROXIMITY,
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by
Shelbie L. Sullivan
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Under the Supervision of Professor Katie E. Mosack

There are an estimated 1.5 million people living with systemic lupus erythematosus (SLE), a
multisystem autoimmune disorder with a high risk of co-morbid health concerns. The
psychological consequences of an SLE diagnosis result in increased daily stress, anticipated
stigma, fears of rejection, and increased self-consciousness, all of which can decrease a patient’s
quality of life. In order to combat these negative experiences, attempts to increase accurate
knowledge of SLE and extinguish SLE misconceptions must be made. The current study aimed
to 1) create a medically informed SLE knowledge questionnaire; 2) determine the rate of
community members’ SLE knowledge; and 3) determine the relation that disease proximity and
educational exposure have on community members’ knowledge of SLE. This novel study is the
first to create an SLE knowledge questionnaire and provide evidence that having a closer
personal relation to SLE increases SLE knowledge, as does having learned about SLE in an
educational setting.

ii

© Copyright by Shelbie L. Sullivan, 2016
All Rights Reserved

iii

To
my mother, my dear friend Samara,
and all those living with lupus – this is for you.
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Development of a Systemic Lupus Erythematosus Knowledge Questionnaire: The
Relationship Among Disease Proximity, Educational Exposure, and Knowledge
Chronic disease affects nearly 50% of Americans, which means approximately 117
million people are living with at least one chronic condition (Ward, Schiller, & Goodman, 2014).
Systemic lupus erythematosus (SLE) is one example of a chronic disease that has physical,
psychological, financial and social implications for individuals who are diagnosed. According to
the American Autoimmune Related Diseases Association (AARDA), in 2011 SLE cost around
$20,000 a year per patient in direct and indirect healthcare costs. Nationally speaking, SLE costs
somewhere between $2.2 billion and $9.6 billion dollars a year.
Systemic lupus erythematosus is a rare and complex multisystem autoimmune disorder
where one’s immune system is overactive and the body attacks its own organ systems (Mak, Ho
& Lau, 2009; NIAMS, 2006). There are four specific variations of the illness cutaneous/discoid
lupus, drug-induced lupus, neonatal lupus, and SLE. However, SLE is the most common
diagnosis and makes up 90% of all broad lupus diseases. SLE is also most commonly referred to
as “lupus,” while the other variations are referred to by their specific name. Due to the
complexity of SLE and the diagnostic process, prevalence rates are quite difficult to calculate.
The Lupus Foundation of America (n.d) reports that there are approximately 1.5 million cases of
lupus and 70% of these cases are SLE-specific. However, newer studies have attempted to gather
statewide prevalence rates rather than national rates (Pons-Estel et al., 2010; Somers et al., 2014;
Feldman, et al., 2013; Helmick et al., 2008). More recent researchers’ findings estimate that there
are 161,000 definite cases and another 322,000 probable cases of SLE to date (Helmick et al.,
2008) and approximately 6 newly diagnosed cases per 100,000 people each year (Pons-Estel et
al., 2010; Somers et al., 2014). This uncertainty about the true number of SLE cases makes
getting appropriate treatments difficult because so many patients are not aware of their diagnosis.
1

The specific cause of this abnormal immune functioning is not fully understood;
however, both genetics and environmental factors play a role in disease onset (Bensler &
Silverman, 2007). The disease is considered an invisible chronic illness due to the manifestations
being largely internal in nature (NIAMS, 2006; Parrondo, 2011). This label is given because
patients experience unique challenges in their life when diagnosed with an invisible illness that
threaten their quality of life (QoL; Brennan & Creaven, 2015; Sutanto et al., 2013). Patients
diagnosed with SLE report excessive uncertainty, hopelessness, and helplessness related to the
experience of their invisible symptoms (Beckerman, Auerbach, & Blanco, 2011). Patients are
also at an increased risk for psychiatric conditions, which further decrease their QoL.
Patients often find that they must learn to identify and care for their physical symptoms
quickly in order to manage their disease more effectively. This ability to monitor one’s disease is
often times difficult as symptom expression and severity is extremely unpredictable (NIAMS,
2006; Lau & Mak, 2009). Patients experience symptoms in flares, which is when symptoms
occur in a variation of severity levels with a varying array of symptoms. The range of SLE
symptom expression varies between mild disease activity and severe disease activity throughout
patients’ lives (NIAMS, 2006). It is estimated that 50% of SLE patients will also manifest severe
complications of the disease: nephritis (kidney inflammation), vasculitis in the central nervous
system (inflammation of brain and spine blood vessels), pulmonary hypertension (deterioration
of lung capillaries), interstitial lung disease (lung tissue scarring causing breathing difficulties),
and stroke (Parrondo, 2011; Lam & Petri, 2005).
A patient’s feelings of distress, guilt, and anxiety are due in large part to the negative
social experiences they have with individuals who do not understand them and their illness
(Brennan & Creaven, 2015; Earnshaw et al., 2012; Sutanto et al., 2013; Hale et al., 2006; Moses,
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Wiggers, Nicholas, & Cockburn, 2005; Kozora, Ellison, & West, 2006). Attempts to understand
how to improve the lives of patients have begun to move towards assessing the awareness that
others, such as medical providers, family and friends and community members have of SLE
(Brennan & Creaven, 2015; Hagger & Orbell, 2003; Karlson et al., 2004; Waldron et al., 2011;
Young et al., 2002). In order to attempt to improve patients’ emotional and physical health new
advocacy efforts need to extend to other groups’ awareness and knowledge of SLE.
Epidemiology and SLE Disparities
The cause of SLE is attributed to a combination of hormones, genetics, and
environmental factors (e.g. ultraviolet rays or various chemical pollutants; Sestak, Nath,
Sawalha, & Harley, 2007; Pons-Estel et a., 2010). Twin studies and familial studies have found
that SLE is genetic in nature and as many as 100 currently identified genetic risk factors exist
that remain latent until an environmental factor triggers onset (Sestak et al., 2007). SLE is
disproportionately found in ethnic minority women and individuals of lower socioeconomic
statuses (SES; Feldman et al., 2013). Genetic linkages, which are the specific order that genes
are expressed on the chromosome, have also been identified within different ethnic groups
(Harley, Kelly, & Kaufman, 2006). These linkages have been examined and many are unique to
African American patients while other linkages have been identified for European-Americans or
Hispanic-Americans (Sestak et al., 2007; Harley, Kelly, & Kaufman, 2006).
It is not clearly understood to what extent environmental factors play a role in the onset
of each case of SLE; however, two factors that have been identified as onset triggers are
exclusively seen in women: estrogen and the XX chromosome (Crampton, Morawski, &
Bolland, 2014). The overall diagnosis rate of SLE in women is 90%, where women are
diagnosed nine times more often than men (Bensler & Silverman, 2007). Poverty and
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disadvantages in one’s environment also plays a direct role in the survival rate of people with
SLE (Durán, Apte, & Alarcón, 2007). A vast amount of scientific evidence has identified that the
dominant group most commonly diagnosed with SLE are women of minority status in low SES
environments (Marengo et al., 2012).
Another disparity that exists for women is being of child-bearing age, which is
considered to be between 15 and 45 years-old (Pons-Estel et al., 2010). Women with SLE who
are pregnant or attempting to get pregnant are considered high risk due to the heightened risk of
first and second-trimester premature births, low birth weights, and fetal deaths (NIAMS, 2006;
Clowse, Magder, Witter, & Petri, 2005). Provided that women of childbearing age are at
heightened risk of SLE onset, attempts to decrease the adverse effects for the baby and the
mother’s health during pregnancy have been made. Medications are monitored more closely
because some are not safe during pregnancy, which means women are taken off medications that
manage their SLE (Clowse et al., 2005). Without these critical medications, disease activity
increases. Increased disease activity during a pregnancy is one of the highest risk factors for
infant mortality (Clowse et al., 2005). A delicate balance must be kept between medication
management, disease activity, and monitoring a fetus’ and a mother’s health during pregnancy.
Over the last 50 years, improvements in medical care have led to increased availability of
medications, the creation of new medications, and new research. All of these advancements have
helped to improve the life expectancy of SLE patients. In the 1950’s, approximately 50% of SLE
patients died within 4 years of symptom expression and today survival rates are higher than 90%
after 5 years (Pons-Estel et al., 2010; Harley, Kelly, & Kaufman, 2006). However, patients still
suffer long-term decreases in QoL and increased medical costs (Pons-Estel et al., 2010). Even
though medical advances have improved survival rates the disproportion of SLE diagnoses in
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low SES and ethnic minority patients are still astronomical compared to non-white patients
(Williams, Kamen, Penfield, & Oates, 2014). Therefore, increasing the awareness that patients
and providers have for higher risk groups could improve the rates of accurate SLE diagnosis.
SLE Education and Interventions
As researchers learn more about SLE and the way that it impacts patients’ lives they have
created various patient education programs (Cunningham & Kashikar-Zuck, 2013; Brown et al.,
2012; Ramos-Remus, Salcedo-Rocha, Prieto-Parra, & Galvan-Villegas, 2000). There have been
two attempts at educating patients about SLE disease knowledge (Konttinen et al., 1991; Young
et al., 2002). The researchers of these studies implemented and assessed the success rate of
patient-specific education programs by providing patients with an educational resource (e.g.
internet education website or patient education pamphlets). However, only two specific
assessments have examined knowledge education with patients and there have been no attempts
to examine the level of knowledge that medical providers, social supports or the general public
have of SLE. The lack of attention given to knowledge levels for these other groups leaves a gap
regarding ways to improve the lives of patients by increasing awareness of SLE.
The first attempt to assess patient knowledge of SLE was in 1991 when Konttinen and
colleagues provided SLE patients with a patient education guide and assessed pre- and post-test
knowledge. Researchers created a patient guidebook that incorporated SLE disease information
and positive coping mechanisms for patients. The researcher’s primary aim was to assess
whether having access to a medically accurate SLE source would produce significant
improvements in patient knowledge of their disease. The second aim was to examine whether
being informed about positive coping behaviors would improve psychological well-being.
Researchers concluded that psychological functioning did not change, but patients’ knowledge of
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SLE did significantly increase over the course of the 8 to 10 weeks that knowledge was assessed.
Konttinen and colleagues (1991) concluded that the improvement that their participants indicated
that patients were interested in learning more about their disease and that learning more about
their disease was beneficial for patients.
Another attempt to test patients’ knowledge utilized an internet based information center
for patients called LupusHelp (Young et al., 2002). The goal was to increase patient knowledge
and researchers wanted to determine if having free online access to pamphlets, videos, and
support groups related to SLE could further increase patients’ knowledge. Patients who
completed the pre- and post-test knowledge test showed significantly improved knowledge.
Indicating that for those who visited this LupusHelp web page and completed both the pre-and
post- tests gained valuable knowledge of SLE. Although patients’ knowledge and well-being
improved the researchers did not extend the benefits of this remote resource to other groups like
the general public, medical providers, and social supporters.
Psychological treatments and therapy options have developed and utilized a more
collaborative technique for including disease education into treatments. Psychoeducation is the
educational component in therapy that involves explaining to the client how treatment will
specifically help their mental health concerns; however, when a patient has a comorbid physical
condition the psychoeducation also includes specific disease information (Keefe, 1996). One
way that psychoeducation is implemented is within the goals of Cognitive-Behavioral Therapy
(CBT) methods (Keefe, 1996; Keefe, Somers, & Martire, 2008; Evers, Karrimaat, Van Riel, &
De Jong, 2002). CBT treatment modules have been created to target the experience of pain
associated rheumatologic conditions (Sharpe, 2003; Haupt et al., 2005). Clinicians use treatment
goals to educate patients on how their disease can be managed and to teach skills specific to the
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symptoms related to SLE (Rinaldi et al., 2006; Haupt et al., 2005). Evidence suggests that
educating patients about their disease in therapy is related to improved health outcomes (Rinaldi
et al., 2006; Thumboo & Strand, 2007).
For SLE patients, interventions that incorporate these CBT therapeutic tools and illnessspecific information are associated with significant reductions in anxiety, depression, stress and
disease activity (Karlson et al., 2004; Zhang, Wei, & Wang, 2012). However, disease education
alone is not indicative of significant psychological improvements (Parker et al., 1988; Ottonello,
2007). Ultimately, improvements in QoL occurs when disease knowledge is incorporated into
psychological treatments. Although encouraging, this results in a disparity because it implies that
only patients receiving psychological treatments are gaining the benefits of these successful
results.
The one research design that involved a social supporter or partner into an SLE-specific
treatment occurred when Karlson and her colleagues (2004) examined the efficacy of a
psychoeducational intervention for SLE patients and had them identify and choose one partner,
either a spouse or a family member, to join them in the intervention. The randomly assigned
treatment pairs received an intervention designed to increase self-efficacy, communication
between the pair about SLE, social support, and problem solving. At the 6-month follow-up,
communication and problem-focused coping improved significantly compared to the control
group. At the 12-month follow-up, social support, patient self-efficacy, and global mental health
of the patient had all improved significantly while fatigue of the patient decreased significantly.
However, global physical function of patients and their disease activity, as measured by the
systemic lupus activity questionnaire (SLAQ), did not significantly improve over the course of a
year. The findings provided evidence of some benefits to having a supporter be a part of an
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intervention but that over time a patient’s physical functioning may not drastically change.
However, the researchers did not incorporate any disease knowledge component to their study.
Future studies should incorporate an SLE-specific knowledge questionnaire to assess an
additional variable related to dyadic relationships.
Although attempts to educate providers on SLE have not been conducted at this time,
researchers have found that patients want their doctors to know more. Waldron and colleagues
(2011) conducted interviews with SLE patients and asked them to recall what their information
needs were at the time of their diagnosis. The researchers wanted to understand how to improve
patients’ disease knowledge satisfaction and how to minimize the difficulties associated with
information gathering. Patients reported feeling that providers were not as accessible as they
wished and that providers did not inform patients of the “full picture” of what SLE is and how it
influences life (Waldron et al., 2011). Providers may not be doing all they can to educate newly
diagnosed patients. This may suggest that providers are not as competent or confident in their
ability to treat and identify SLE. However, conclusions cannot be substantiated due to the lack of
information regarding how knowledgeable various medical providers are of SLE. Improved SLE
education for medical providers could be a way to counteract the negative experiences that
patients report having with their medical providers (Mak et al., 2009).
Common Sense Model of Illness
The Common Sense Model of Illness (CSM) is a theoretical framework that informs
patients’ experiences living with a chronic illness and how cognitive and emotional factors
influence coping behaviors and outcomes (Leventhal, Meyer, & Nerenz, 1980). The model
proposes that a patient’s perceptions about the illness experience influence the overall illness
representation, coping strategies, and future health outcomes. Patients’ perception their illness
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and whether they employ positive or negative coping strategies has a direct relationship between
disease severity and health outcomes (Cameron, 2003).
There are five components that influence how illness perceptions develop: identity,
cause, timeline, consequences, and curability/controllability (Hale, Treharne, & Kitan, 2007).
The identity component labels a condition and the symptoms that are experienced. Having labels
allows the patient to be able to identify and continue to re-identify the schematic representation
of their disease. Recurrent symptoms strengthen the labels while new symptoms provide more
detail regarding the disease. The cause component refers to the individualistic ideas about the
perceived cause of the condition. The cause can include information gathered from four contexts:
the biological cause (immune system), emotional cause (stress), environmental cause (pollution)
and psychological cause (personality or mental state; Hagger & Orbell, 2003; Diefenbach &
Leventhal, 1996). Information gathered about cause does not necessarily involve factual
information regarding the cause; instead, these representations are often based on personal
experiences and information gained through the opinions of others. Significant others, medical
providers, and the media all influence the individual’s belief about what caused their diagnosis.
The timeline dimension is the belief about how long the condition may last,
understanding if an illness is chronic or acute. As the individual adds new details to their illness
representation patients re-evaluate their timeline representation. The consequence dimension is
the component of the model that addresses beliefs regarding the impact an illness has on a person
physically and socially. Only over time does an individual begin to identify accurate beliefs
rather than irrational ones (Hale, Treharne, & Kitan, 2007). Theoretically, the longer a patient is
diagnosed with a disease his or her understanding of the disease becomes more accurate. Finally,
the curability/controllability component addresses the beliefs an individual has regarding
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whether the condition can be cured and/or controlled (Leventhal, Meyer, & Nerenz, 1980). This
involves understandings of treatment options and the effects of treatments (i.e., management vs.
curable). Information about each of the five CSM components are continuously collected and
evaluated throughout a patient’s life. Providing opportunities to give patients accurate SLE
information could aid in the process of re-evaluating inaccurate illness representations and create
a new more accurate representation based on accurate knowledge.
According to the CSM, information is gathered in three different ways. The first is
through general or layperson information gained from previous social communication and
cultural knowledge of the illness. Therefore, individuals who interact with patients need to be
aware and knowledgeable of the disease because illness representations are partially based off
the knowledge that individuals around the patient (e.g., community) have of SLE. This means
that the general public should understand SLE and how it impacts patients. The second is
information gained from external social environments from significant others or expert sources
(e.g. doctor). This area of information gathering is important because if experts and significant
others do not have accurate knowledge of SLE the patient is at an increased risk of being
exposed to more misinformation. Accurate transmission of knowledge is critical and those who
are close to a patient need to be accurately informed. The final source of information gathering
occurs due to the subjective experience of a patient’s illness. Throughout life the illness
representation evolves (Hale, Treharne, & Kitan, 2007; Leventhal, Meyer, & Nerenz, 1980).
Patients need to remain informed of their diagnosis and how it will affect them.
An individual creates a mental representation of his or her illness using concrete and
abstract information that is gathered throughout the course of the illness. This information is then
associated with the overall disease experience; this linking of information to the individual’s
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illness representation is automatic and intrusive (Hagger & Orbell, 2003). As a person
experiences more intensified symptoms he or she appraises the information gathered to
determine the level of threat perceived about the illness based on current symptoms. The
appraisal cycle is what leads to the construction of an illness representation. For example, when
presenting symptoms activate a negative emotional response (i.e. fear, sadness, worry) the
symptoms and the association with negativity strengthen the representation that the symptom is
more dangerous (Cameron, 2003). Ultimately, the more intense an illness is and the more
symptoms experienced, the more likely a patient is to increase the subjective association of the
illness being dangerous. If patients believe they have coping skills to combat their negative
experience, then they can employ these skills. If patients do not believe they have the appropriate
coping skills, they remain in a high level of distress.
The CSM theorizes how individuals identify and process information regarding their
illness, how that information is integrated to provide a representation of their illness, and how to
employ appropriate coping behaviors (Hagger & Orbell, 2003). As someone obtains new
information about his or her condition he or she reevaluate their illness representation. By
improving accurate SLE disease knowledge patients can work to reframe their illness
representation (Cameron, 2003). Improving the awareness and accurate knowledge of SLE
among the general public, medical providers and social supporters could be a way to interrupt
false information transmission to the patient. The more accurate and realistic an illness
representation is the more likely patients are to utilize appropriate coping behaviors for
managing SLE (e.g. seeking medical care, avoiding risky behaviors), which improves disease
experience and QoL. Therefore, it is important for a patient’s illness representation to be
informed by accurate knowledge.
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Implications for Knowledge Assessment in SLE
Having a rare chronic illness has a large impact on a patient’s life. By having an accurate
understanding and awareness of physical and psychological symptoms of SLE patients’ illness
experiences could be improved. Increasing knowledge is a way to raise awareness and combat
negative disease experiences; therefore, assessing SLE knowledge can have implications for
helping patients, medical providers, and supporters of patients (Hale et al., 2006). The next
subheadings address why the assessment of accurate SLE knowledge is important.
Physical Complications. People living with SLE experience a multitude of physical
symptoms, including but not limited to, inflammation, joint pain, fatigue, skin rashes, and severe
deterioration of one or several organ systems (Sutanto et al., 2013). Fatigue is most persistent
and often results in low muscle strength, which is a concern in SLE patients because the muscles
and joints are at increased risk of deterioration (Parrondo, 2011). Symptoms of SLE do not occur
independently; rather, they occur together and exacerbate each other. This interaction between
physical symptoms and the disease progression is important to understand because symptom
flares vary in severity. Is important for patients to be aware of their limitations when flares are
severe because disease activity is one of the most predictive factors of patients’ health status
(Dobkin et al.,1999; Rinaldi et al., 2006).
The complexity of SLE often leads to a lengthy and daunting diagnostic process.
Diagnosing SLE requires upwards of 20 tests used in combination and it is common to take up to
5 or more years to receive a diagnosis (Lam & Petri, 2005; NIAMS, 2008). The American
College of Rheumatology developed the 11 diagnostic criteria for diagnosing SLE (Hochberg,
1997). The individual must exhibit at least four criteria, at least one medical test confirmation
and one affected organ system. The diagnostic categories include rashes (malar or discord),
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photosensitivity, mouth sores, arthritic symptoms, lung/heart inflammation, renal disorder,
neurological disorder, hematologic disorder, immunological disorder, and a positive Antinuclear
Antibody (ANA) test. There is no cure for SLE and the progressive style of disease activity is
serious. The longer patients go without receiving a diagnosis, the longer they go without the
appropriate treatments (Lau & Mak, 2009). Improving knowledge of SLE symptoms among
those at higher risk for SLE could lead to an earlier diagnosis because individuals could identify
symptoms earlier and see out the appropriate care. Additionally, improving medical providers’
knowledge of SLE symptoms could lead to an earlier diagnosis window for future patients
because they would be aware of the combination of symptoms that constitute an SLE diagnosis.
SLE is referred to as “the great imitator” because of the way that symptoms mimic a
variety of other chronic illnesses, such as rheumatoid arthritis, fibromyalgia, hypothyroidism,
multiple sclerosis, and more general dermatology disorders, endocrine system dysfunctions, and
infections (Sutanto et al., 2013; Benseler & Silverman, 2007; NIAMS, 2008; Cojocaru,
Cojocaru, Silosi, & Vrabie, 2001). It is critical for patients to know that as their overactive
immune system continues to attacks various healthy organ systems they are at an increased risk
of a variety of additional life-threatening comorbid diseases (Pons-Estel et al., 2010). People
living with SLE are at increased risk for pulmonary, cardiac, gastrointestinal, ocular,
hematologic and neuropsychiatric disorders (Parrondo, 2011). The physical complications of
SLE go through ebbs and flows and the risk of comorbid diseases is high. Being aware of the
complications that symptoms present is important to help patients manage their SLE daily.
Psychological Complications. Danoff-Burg and Friedberg (2009) assessed the
satisfaction of patients’ needs and found that 91% of their SLE sample reported a psychological
need being unmet. Not only do patients’ needs remain unmet, but they also experience a general
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negative affect and are more susceptible to psychological distress, such as additional stress and
worry (Moses, Wiggers, Nicholas, & Cockburn, 2005). The increase of distress and
dissatisfaction lead individuals to be at an increased risk of more severe mental health concerns,
which, in turn, exacerbate disease activity. Nery and colleagues (2007) reported that life events
contribute to the onset, recurrence, and severity of depression and that overall psychological
distress is associated with life events. For example, when life events related to an SLE diagnosis
are perceived as negative or stressful a patient’s life satisfaction and report of quality of life
decrease (Bennett, Fuertes, Keitel, & Phillips, 2011; Earnshaw, Quinn, & Park, 2012). The
nature of SLE continues to influence the mental health of patients far beyond the diagnosis.
Comorbid psychological disorders occur more often in SLE patients compared to the
general public. Mood disorders such as major depressive disorder (MDD; single episode and
recurrent episodes), depression due to a general medical condition, and depressive episodes not
otherwise specified (NOS) have been reported in up to 69% of SLE patients (Nery et al., 2008).
MDD, is in fact, the most diagnosed disorder for patients with SLE; the lifetime prevalence rate
has been estimated to be 49.2% (Kozora, Ellison, & West, 2006; Nery et al., 2008; Stojanovich,
Zandman-Goddard, Pavlovich, & Sikanich, 2007; Julian et al., 2009; Nery et al., 2007).
However, the national average for receiving an MDD diagnosis in life is only 20.8% (Kessler et
al., 2005). Unfortunately, providers and patients often times attribute depressive feelings to a
general low mood and do not take the necessary precautions to help manage the true severity of
depression (Giffords, 2003).
Disease activity has a direct relationship to psychological symptoms because as a
patient’s disease severity increases their reports of anxiety symptoms increase as well (Bachen,
Chesney, & Criswell, 2009). Anxiety is another common psychological concern for SLE
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patients, with a lifetime prevalence rate being as high as 52% (Meszaros, Perl, & Faraone, 2012;
Bachen et al., 2009; Nery et al., 2008; Stojanovich et al., 2007; Beckerman et al., 2011).
However, lifetime prevalence of anxiety disorders in the general population is lower at 28.8%
(Kessler et al., 2005). In a large all female sample only 4.3% of the sample met diagnostic
criteria for generalized anxiety disorder (GAD) at the time of the study (Bachen et al., 2009).
Many factors go into having a current GAD diagnosis and just because someone does not meet
the necessary criteria to receive a formal diagnosis does not mean the level of worry and anxious
feelings experienced do not negatively impact the patients’ life. Instead, some level of anxiety
related diagnosis is experienced at a relatively high rate. Anxiety-related disorders such as
specific phobia (24%), panic disorder (16%), and obsessive-compulsive disorder (9%) were also
diagnosed in SLE patients at a significantly higher rate than the general population sample
(Bachen et al., 2009). Although the specific diagnosis may vary across patients, the rate of
anxiety and anxiety-related disorders is severely elevated in this disease population.
Psychosis is also a serious concern for SLE patients. It is diagnosed in 2-3% of SLE
patients but as high as 31-39% for those on high doses of corticosteroids (Pego-Reigosa &
Isenberg, 2008). Long-term corticosteroid medication use has adverse effects on hippocampus
receptors which have been found to directly cause hallucinations and paranoia (Nery et al., 2008;
Mak et al., 2009). Corticosteroids are one of the more dangerous treatment medications that are
used intermediately for patients throughout the course of their life. Due to the high toxicity, the
recommendation is that any steroid medication should be used in the lowest dose possible, for
the shortest amount of time that results in disease management (Chatham & Kimberly, 2001).
Corticosteroids minimize the progression of autoantibodies that attack the healthy cells and
decrease inflammation; therefore, patients who experience more severe flares, cutaneous skin
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lesions, advanced SLE lung disease, renal disease, and severe inflammation are prescribed
steroid medications (Chatham & Kimberly, 2001). Even though providers should only prescribe
corticosteroids in small doses, some patients are prescribed them for substantially longer periods
of time, which increases patients’ susceptibility to additional medical conditions and increased
psychological concerns (Chatham & Kimberly, 2001; Pego-Reigosa & Isenberg, 2008).
Quality of Life. Quality of life (QoL) has been identified as an indicator of the health
status in patients with chronic diseases (Freire et al., 2011). In general, patients with SLE report
decreased satisfaction with their lives due to their physical and mental health concerns. Those
with more severe SLE report worsened physical health and have decreased social interactions,
which leads to less supportive relationships (Panopalis & Clarke, 2006; Dobkin et al., 1999).
Patients variability in their physical (e.g. increased symptom severity/flares), mental (e.g. general
low affect and psychiatric disorders), and social (e.g. relationships with physicians) experiences
place these patients at increase susceptibility of lower QoL. Compared to the average American
adult, SLE patients are functioning at a lower level than non-diagnosed individuals (Pons-Estel et
al., 2010). For individuals living with chronic illness, QoL is critical. Their life is often
interrupted by their disease. For patients living with SLE, their experiences are so unique that
they are susceptible to additional factors that threaten their QoL (Yazdany, 2011). Factors
influencing SLE-QoL, include age, duration of illness, amount of education, self-efficacy,
knowledge of lupus, and social support (Thumboo & Strand, 2007; McElhone et al., 2007).
Stigmatization. The invisibility of SLE increases patients’ daily stress level because they
can experience isolation and stigmatization from the public, medical providers, and even their
social support networks (Hale et al., 2006; Kool & Greene, 2012; Kool et al., 2010). Feelings of
anticipated stigma, fears of rejection, increased self-consciousness, and reports of guilt regarding
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their diagnosis are common for someone living with SLE (Earnshaw et al., 2012; Sutanto et al.,
2013). Patients’ experiences with negative social interactions increase their stress levels and lead
to perceptions of less support. Patients report that when individuals such as friends, family, and
work colleagues do not fully understand their disease they feel stigmatized for their experiences,
which perpetuates their distress (Hale et al., 2006; Earnshaw et al., 2012). Feeling misunderstood
causes more distress and is associated with decreased mental and physical health of SLE patients
(Dobkin, et al., 1998).
Another source of increased worry that patients feel is related to the self-conscious
feelings experienced when visiting physicians (Beckerman et al., 2011). Patients have reported
that they worry about physicians judging them during their medical appointments and these
worries increase when patients believe their doctors perceive them as uneducated. SLE is
diagnosed more in individuals who are from lower SES populations and this increased distress of
stigmatization because of low education has a major impact on patients’ perceptions of
themselves. This stigma worry is an additional barrier for SLE patients when it comes to seeking
appropriate medical care (Feldman et al., 2013). Patients express concern that they do not want
to look bad in front of their health care professionals and if they perceive their provider is likely
to stigmatize them, they are likely to avoid going.
Medication Adherence. When SLE is not managed properly, disease activity and
complications increase (Lau & Mak, 2009). Medication use is the most common treatment for
SLE because of the direct biological influence. Medication non-adherence is also a contributor to
the increased health care cost of SLE (Lau & Mak, 2009). As disease activity increases so does
the cost of care for an individual with SLE, this often relates to the necessary hospitalization
stays that are often required when disease activity is severe (Holloway et al., 2014). Non-
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adherence rates in patients are as high as 76% which can be extremely dangerous for a patient’s
life, both physically and mentally (Costedoat-Chalumeau et al., 2013).
Patient’s knowledge of treatment options and his or her belief of the necessity for correct
adherence has also been associated with higher non-adherence rates (Costedoat-Chalumeau et
al., 2013; Chambers, Raine, Rahman, & Isenberg, 2009). Increased psychological distress, most
specifically depression, also threatens the consistency and accuracy of medication adherence
(Marengo et al., 2012; Coleman et al., 2012). Since SLE patients are at higher risk for
depression, they are inherently more susceptible to poor medication adherence (Julian et al.,
2009). Additionally, just as patients sometimes avoid doctor appointments when they feel that
their physician judges them, poor rapport with a provider also plays a role in the individual’s
non-adherence. If a patient feels unheard and disregarded by their provider, they are less likely to
inform their physicians of new or worsening symptoms (Sutanto et al., 2013). Increased rates of
psychological distress, poor physician relationships and a lack of information regarding the
importance of accurate medication use all can contribute to poor medication adherence.
Benefits of Disease-Specific Questionnaires
Previous researchers have explored the importance of assessing specific disease
knowledge. Through more focused assessments of disease knowledge researchers are better able
to understand levels of knowledge among various groups. Specifically, these research designs
provide opportunities to assess what knowledge patients do or do not have, what medical
providers know and where gaps of knowledge exist, and assess the level of knowledge that
family and friends and the general public have of the disease. Further examination of disease
knowledge could be a way to increase knowledge and awareness of SLE while concurrently
decreasing stigmatization. Since no SLE-specific knowledge questionnaire exists, understanding
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how other disease-specific knowledge questionnaires have been designed and implemented is
informative to understand the process that developing an SLE-specific questionnaire would take.
Carpenter and colleagues (2009) created a new and valid general knowledge
questionnaire to assess Alzheimer’s disease (AD) knowledge. They developed a pool of
questions that were previously used in other measures to assess AD knowledge within patient,
professional, and community samples. This provided the researchers the opportunity to gather a
wide range of items for the new questionnaire, which consisted of questions targeting risk
factors, assessment and diagnosis, symptoms, course, life impact, caregiving and treatment. The
final product consisted of true/false items that allowed for a short and quick questionnaire.
Knowledge was significantly higher for those who had attended a support group for dementia
and for those who worked with patients with dementia than those who had not, those who were
college students or those who worked in a senior center (Carpenter, Balsis, Otilngam, Hanson, &
Gatz, 2009). Findings suggest that there are group differences in disease knowledge given an
individual’s awareness of AD. Specifically, the more personal experience and awareness that
participants had was reflected in their AD knowledge.
Another example of assessing disease-specific knowledge is for diabetes-specific
knowledge questionnaires. Multiple diabetes knowledge questionnaires have been developed and
tested. Fitzgerald and colleagues (1998) examined the reliability and validity of a brief diabetes
knowledge test while other researchers have created and examined alternative measurement tools
(e.g. Revised Diabetes Knowledge scale; Collins, Mughal, Barnett, Fitgerald, & Lloyd, 2010).
Fitzgerald and colleagues (1998) compared patient scores that were collected from two different
medical centers. They determined that there were differences among scores depending on the
medical setting and patient populations and there was a degree of variability between groups.
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Collins et al. (2010) additionally compared the effects that different response formats could have
on scores. The new measure was adapted to have binary responses based on the multiple-choice
items found on the Simplified Diabetes Knowledge Scale. Results indicated that average scores
were remarkably similar (62% (multiple choice) compared to 65% (true/false)). The responses
style does not seem to affect the outcomes when it comes to testing disease-specific knowledge.
Many other disease-specific knowledge questionnaires exist, including ones assessing
STD and HIV knowledge (Carey & Schroder, 2002), heart disease (Bergman, Reeve, Moser,
Scholl, & Klein, 2011; Wagner, Lacey, Chyun, & Abbott, 2005), chronic obstructive pulmonary
disease (OCPD; White, Walker, Roberts, Kalisky, & White, 2006), cystic fibrosis (Siklosi,
Gallagher, & McKone, 2010), multiple sclerosis (Giordano et al., 2010), fibromyalgia (Suda,
Jennings, Bueno, & Natour, 2012), osteoporosis (Winzenberg, Oldenburg, Frendin, & Jones,
2003) and arthritis (Edworthy, Devins, & Watson, 1995). Researchers have also conducted
studies to examine the level of knowledge that different groups have. Disease-specific
knowledge questionnaires have been used in various disease populations and have been used in
conjunction with additional educational intervention material to improve the awareness that
patient populations and significant others have of various diseases.
Purpose of Proposed Study
Assessing SLE-knowledge could provide increasingly important benefits to a variety of
groups by working to reframe the social perspective that others have on this complex invisible
disease. Creating additional educational material that could be used to improve the knowledge
that community members have of SLE might help raise awareness of the disease and decrease
SLE stigma. Improving patients’ knowledge of SLE might encourage them to take a more active
role in disease management by being aware of disease outcomes. Increasing the knowledge that
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medical providers have of SLE could help speed up the diagnosis process and improve patients’
outcomes. Decreasing the stigmatizing misconceptions of SLE could further improve patients’
relations with family, friends and employers. Together, increasing knowledge about SLE could
help facilitate increased awareness, reductions in stigmatization, and improved patient outcomes.
Assessing SLE knowledge in a community sample is the first step in an overall research
agenda to understand what the level of accurate knowledge and awareness is of SLE. This is the
first study of its kind to create an SLE-specific knowledge measurement tool in order to assess
general knowledge of SLE in a community sample. It is the aim of the following proposal to
develop the first SLE specific knowledge questionnaire and use the questionnaire to explore SLE
knowledge and the influence of educational exposure and disease proximity. This study involves
the following research questions and hypotheses:
RQ1) What are the common topics that providers identified as being important to be
included in the Lupus Knowledge Questionnaire?
RQ2) How do participants in a community sample score on the LKQ?
H1) Individuals with educational exposure of SLE will have higher scores on the
LKQ than those who have no previous educational exposure to SLE.
H2) Individuals who have closer disease proximity to SLE will have higher scores
on the LKQ than those who know no one with SLE.
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Method
The current study occurred in four phases guided by adaptations from the questionnaire
development protocol created by the European Organization for Research and Treatment of
Cancer (EORTC; Johnson et al., 2011). The protocol had been previously adapted and used by
researchers to create disease knowledge questionnaires (Jaglarz, Tomaszewski, Kamzol,
Puskulluoglu, & Krzemieniecki, 2014), quality of life measures (Wheelwright et al., 2013), and
patient outcome measures (Denniston, Kyte, Calvert, & Burr, 2014; Reeve et al., 2013).
Phase 1 consisted of interviews with medical experts. Phase 2 incorporated drafting a
version of the lupus knowledge questionnaire (LKQ); items were created by utilizing qualitative
methods to analyze interview responses and conducting a thorough literature review of
educational material used by the Lupus Foundation of American to inform individuals about
SLE. Phase 3 consisted of the draft version being reviewed for relevance, accuracy, and clarity
by the same experts who were interviewed during Phase 1. Edits to the LKQ were made based on
results from a regression analysis and feedback from the providers. Phase 4 concluded the
proposed study and consisted of two administrations of the LKQ. The first sample was given the
draft version of the LKQ and a unique second community samples was administered the revised
version of the LKQ. The samples were used to gather initial psychometric data: internal
consistency, item analyses (item difficulty/discrimination, readability) and data on participants’
LKQ scores. Institutional Review Board approval was obtained from the university to conduct all
aspects of this study.
Phase 1: Conducting Provider Interviews
Participants. Three medical providers (2=MDs; 1= Nurse Practitioner) were recruited to
consult as experts. Two of the providers were male and one provider was female. Previous
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researchers recommend using a minimum of two experts to act as consultants to gather
knowledge data; therefore, the use of three experts was considered adequate (Siklosi et al., 2010;
White et al., 2006; Jaglarz et al., 2014). In order to participate in the study, the providers needed
to have previous experience diagnosing, treating and caring for SLE patients. The medical
providers were recruited from medical centers in Indiana through existing personal and
professional relationships.
Procedure. To address Research Question #1, medical providers were asked to complete
a one-on-one interview to gather qualitative data of relevant SLE knowledge topics. The
interview protocol was informed by the dimensions of the Common Sense Model of Illness
because of the focus on disease experience and representation. Interviews are commonly used
methods used to collect content related to a topic (Gill, Stewart, Treasure, & Chadwick, 2008).
Measures and Materials. Materials included a hand held recording device and the
interview protocol. Responses to the interview were recorded to allow for easy reexamination of
the interview content. Interviews were conducted over the phone and experts were first asked to
consent to the study before completing the interview. Questions in the semi-structured interview
protocol included, what resources do you have at your disposal to assist you in providing
education/knowledge to your SLE patients, what questions regarding SLE do patients not ask
about that they should, and what should people know about SLE to have a good general
understanding of the illness and how it is experienced by people? (See Appendix A for Full
Interview Protocol.)
Phase 2: Reviewing Patient Education and Interview Data
Procedure. Previous researches who have created disease-specific knowledge
questionnaires begin by gathering or adapting a pool of items from previously validated studies

23

that assessed the disease in question (Davis, 1992; Giordano et al., 2010; Carpenter et al., 2009;
Siklosi et al., 2010). Alternatively, researchers gather general information regarding accurate
disease information from both literature and expert individuals (e.g., physicians, psychologists,
nurses, nutritionists; Siklosi et al., 2010; White et al., 2006; Wagner et al., 2005). Given that the
LKQ is the first of its kind, there were no existing questionnaires to assess. Therefore, only the
latter method of item creation was used in the current study.
First, I conducted a literature review to gather information regarding educational
information on SLE. Secondly, I used the medical providers’ interviews to guide item creation.
Finally, I assessed materials used by the Lupus Foundation of American to inform patients,
social supporters, medical providers and the general public regarding SLE.
A true and false response format with a “don’t know” option was utilized for the LKQ;
this was a commonly endorsed response style used to develop disease knowledge questionnaires
(Carpenter et al., 2009; Edworthy, Devins, & Watson, 1995). This option allowed for easier
administration and more accurate representation of factual knowledge, as compared to a
multiple-choice design, which is more beneficial for attitude questions (Beatty & Herrmann,
1995; Poe, Seeman, McLaughlin, Mehl, & Dietz, 1988). When a “don’t know” option does not
exist participants have reported feeling more compelled to respond without having any basis for
their answer, resulting in incorrect representations of knowledge. Additionally, including the
“don’t know” option allowed identification of items that resulted in higher awareness versus
lower awareness.
Materials. I used the content from the interviews to inform the initial content of the
items. Additional support, in terms of wording or more specific details, was gathered through the
examination of pamphlets developed by the Lupus Foundation of America to educate
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individuals. Therefore, the materials used to inform the items remained the interviews and the
pamphlets from the LFA.
Analyses. Qualitative content methods were used to inform the collection of items on the
LKQ. I developed a pool of items based off information gathered from the interviews and the
pamphlet content. Components of directed content analysis as well as standard disease-specific
knowledge questionnaire methods were utilized to determine the content of the LKQ items.
Aspects of a directed content analysis were applied because of this method’s focus on being
informed by an existing theory (Hsieh & Shannon, 2006). Items focused on general knowledge
of SLE rather than very nuanced aspects of the SLE-disease experience (Johnson et al., 2011;
Jaglarz et al., 2014; White et al., 2006; Hennell, Brownsell, & Dawson, 2004, & Holloway et al.,
2014). The CSM’s dimensions (identity, cause, time-line, consequences, and curability/
controllability) were used to inform the interview questions and items’ final content (Hagger &
Orbell, 2003; Hale, Treharne, & Kitas, 2007; Potter & Levine-Donnerstein, 1999).
The initial step of item creation occurred by assessing the broad content areas that the
providers reported as being important through the interviews. After that, the broad themes were
described and elaborated on by compiling all the interviewers’ interviews. After this broad step
was taken the pamphlets were utilized to gather more specific factual information based on the
providers’ answers. The pamphlets allowed for me to fill in gaps from the interviews. For
example, the item related to skin rashes was discussed by all three providers and it was covered
in the pamphlets. Therefore, that item was unanimously supported. Another example is with the
item that asked if SLE is called the great imitator. For this item, the providers broadly spoke of
SLE as being difficult to diagnose because it mimics other conditions. However, the pamphlets
specifically used this verbiage; thus, the pamphlet was used to create the specific item content.
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Phase 3: Verifying and Revising LKQ Draft
Participants. The same medical providers from Phase 1 reviewed the LKQ-draft version
and provided feedback on the relevance of the items as well as provided suggestions on item
clarity and/or accuracy. Utilizing experts to inform and review disease specific questionnaire is
commonly used to confirm the content validity of a measure (Johnson et al., 2011; Jaglarz et al.,
2014; White et al., 2006; Hennell, Brownsell, & Dawson, 2004, & Holloway et al., 2014).
Procedure. Verification and content validity was assessed by having the medical
providers complete the Content Validity Index (CVI; Beck & Gable, 2001; Polit & Beck, 2006).
The providers were sent the draft version of the LKQ along with the CVI to rate each item on
relevance and accuracy. After the providers rated the content and provided feedback, appropriate
changes were made. For example, if providers gave an item a score of 1 or 2 (see below) and
provided feedback for the item, that feedback was incorporated and the item was changed to
make it a highly relevant item. The editing involved correcting the wording of the item and
increasing clarity of the items based on the additional feedback that the providers left. If an item
was not considered relevant the providers were asked to give feedback that they believed would
make that item highly relevant. After all of the providers’ feedback was incorporated the revised
version was generated. (See Appendix B for the Provider Verification Documents.)
Measures. The following measures were given to the three medical providers and data
were used to inform any changes that took place when creating the revised version of the LKQ.
Content Validity Index Scale. The Content Validity Index Scale (CVI) is a method of
quantifying content validity based on expert ratings (Polit & Beck, 2006). On the CVI, the
providers were asked to give feedback on item relevance on a 4 point Likert-type scale (1 = not
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relevant, 2 = somewhat relevant, 3 = quite relevant, 4 = highly relevant) and provide feedback
regarding the accuracy and clarity of the medical facts represented in the items.
Analyses. Scores were calculated based off the CVI procedure. A CVI value was
computed for each item on the scale (I-CVI). Among the literature there was a lack of clarity
regarding the specific method that researchers have used to assess each item’s content value
(Lynn, 1986; Polit & Beck, 2006). For the current study, the method used to calculate the I-CVI
was conducted by having the relevance scores of each item tabulated into not relevant (ratings of
1 and 2) and relevant (ratings of 3 or 4). The I-CVI was then computed by summing the three
scores that each item was awarded and then it was divided by the number of experts (Polit &
Beck, 2006). However, if a provider gave written clarity or accuracy feedback those edits were
made and then the item was considered a 4 so that score overrode the score of one or two. (See
Appendix D for CVI verification feedback)
Lupus Knowledge Questionnaire-Draft (LKQ). The draft version of the LKQ was sent to
the providers and consisted of 38 items related to central domains of SLE knowledge. The items
were informed by the theoretical framework outlined by the CSM and the item content was
gathered from a literature review of patient education material and medical provider interviews.
Items were created with a True/False and “don’t know” structure. Each item was assessed by the
three medical providers. (See Appendix E for the LKQ items in the CSM dimensions.)
Phase 4: Testing the LKQ and the LKQ-R
Participants. The final phase of the current study consisted of two full-scale
administrations of the LKQ. The draft-LKQ was first distributed to a sample size of 336
participants. Of those, 192 identified as female (57.1%) and the majority of the sample identified
as Caucasian/White (N = 278; 82.7%). The mean age was 21.5 (SD=1.82) with ages ranging
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from 18 to 24 years old. Just over half of the sample was enrolled in college in some capacity,
part-time (N=21; 6.3%) or full-time (N=165; 49.1%; Table 1: Frequency of Demographic
Variables).
The LKQ-R was distributed to a second independent community sample of 241
participants. There were a total of 237 participants who participated in the second administration
of the revised LKQ. However, fewer participants’ data were used for the final analyses. One of
the many edits made to the LKQ-R was to include a validity item (item 20: Please answer “true”
for this item). After initial demographic data were collected and analyzed 49 participants
incorrectly answered the validity question by choosing doesn’t know rather than true. Therefore,
those 49 individuals’ data were excluded from the remaining analyses. Additionally, four
individuals did not provide an answer at all. In order to treat the validity item as intended, these
four individuals were also excluded. The final sample size for the second administration was 188
participants.
Of the included participants, the majority were female (N=144, 76.7%). The average age
of the participants was 33 (SD=6.11) and ages ranged from 20 to 54 years old. Most of the
sample identified as Caucasian/White (N = 154; 83.2%) and followed by African American
(N=10, 5.4%). Approximately ¾ of the participants were married (N=173, 73.3%). The Average
years of education was 15.6 (SD=2.24; see table 8 for Frequency of Demographic Variables).
Procedure. The same procedure was used to recruit participants from both community
samples. Participants were recruited by students who were enrolled in a combined undergraduate
and graduate psychology course to participate in an online survey through surveymonkey.com.
As a course requirement, students had to recruit participants through the use of a snowball
sampling method such that each study approached at least one possible participant and asked that
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participant to identify at least one more potential participants and so on (Patton, 1990). Students
in an advanced psychology laboratory class recruited eight English-speaking community
members to complete the online survey. All students involved in data collection were required to
complete training in the ethical conduct of research and alternative assignments were provided to
reduce the likelihood of data fabrication. Parents provided informed consent prior to completing
the full survey. The first sample consisted of young adults and they had to be between age 18 to
24. The second sample consisted of adults who had to be a parent. Class research credit was
given to the students for recruiting effort and students were not penalized for failing to recruit the
required number of participants. The participants completed a battery of questionnaires aside
from the current studies’ measures. The data collected for the current study were collected as part
of a larger data collection project; thus, other studies’ data were collected concurrently. For this
study the data gathered from both samples included informed consent, demographic survey
items, perceptions of knowledge items, disease proximity and educational exposure items, and
the appropriate LKQ version.
Measures. Participants from both samples were asked to complete the following
measures. The first sample completed the draft version of the LKQ and the second sample
completed the revised version of the LKQ:
Demographics. The items included asked participants about their age, race/ ethnicity,
level of education, and marital status. (See Appendix C for Demographic Questions.)
Disease Proximity to SLE. Participants were asked to indicate their relation to SLE based
on four yes/no items meant to assess disease proximity. The disease proximity items were used
to determine whether the individual had close proximity to SLE due to personally being
diagnosed with SLE, having immediate family members diagnosed, extended family family
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diagnosed, or if they knew anyone else with SLE. Participants were offered the option to skip the
disease proximity items with the assurance that they would not be penalized. If participants
answered “yes” to having known a family member (immediate or extended) or another person
with SLE they were also asked to provide a description of their relation to the participant (ex.
Cousin, friend, co-worker; See Appendix C for Disease Proximity Items).
For the purposes of analysis, due to the overlap of endorsed proximity, I had to categorize
the groups as the following: group 1 consisted of people who reported having personal SLE
and/or knew a family member (immediate and/or extended) with SLE; group 2 consisted of
participants who indicated knowing someone else with SLE; group 3 consisted of people who
reported having none of the above proximities to SLE. Due to the low number of individuals
who reported personally having SLE or reported having a family member diagnosed with SLE,
those individuals who did endorse that item were automatically placed into group 1. This
occurred regardless of any additional endorsement of knowing someone else with SLE. Those
individuals who were in group 2, only endorsed knowing someone else. Therefore, having a
closer proximity meant a participant’s data were used within that closer proximity group.
Educational Exposure to SLE. Participants were also asked to indicate their educational
exposure to SLE based on four yes/no items meant to assess their exposure to SLE-disease
information that they gathered through a learning related environment. The educational exposure
items included questions related to whether the participant had heard of SLE, had they attended a
lecture on SLE, had they learned about SLE in a class, and had they read about SLE. (See
Appendix C for Educational Exposure Items).
For the purposes of analysis, to determine groups for the educational exposure groups
participants were similarly imposed into the various groups. I had to categorize the groups as the
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following: group 1 consisted of people who reported having heard of SLE; group 2 consisted of
participants who indicated having read about SLE, learning about SLE in a class, and/or
attending a lecture on SLE; group 3 consisted of people who reported having none of the above
exposures to SLE. Due to the low number of individuals who reported having a deeper
educational exposure to SLE, those individuals who did endorse that item were automatically
placed into group 2. This occurred regardless of any additional endorsement of hearing about
SLE. Those individuals who were in group 1, only endorsed having heard of SLE. Therefore,
having a deeper educational experience meant a participant’s data were used within that deeper
educational group.
Perception of Knowledge. Participants were asked to rate their perceived level of
knowledge before and after taking the knowledge questionnaire. Prior to the participants
completing the LKQ they were asked to rate how confident they were about their knowledge of
SLE (1= Not Confident, 5= Extremely Confident). After participants completed the LKQ they
were asked to report their perceived score on the LKQ (0-100%) as well as how well they
perceived their knowledge of lupus to compare to the average person (1= I have more knowledge
than the average person, 5= I know nothing compared to the average person; See Appendix C).
Lupus Knowledge Questionnaire-Draft (LKQ). The draft version of the LKQ that was
administered to the first community sample consisted of 38 items related to the central domains
of lupus knowledge identified during the phases of questionnaire development. Items were
created with a True/False and “don’t know” structure (see Appendix F for Draft Version).
Lupus Knowledge Questionnaire-Revised (LKQ-R). The revised version of the LKQ
was created after data was gathered from the initial sample of participants and the CVI feedback
was incorporated. The edited version consisted of 34 items related to the central domains of
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lupus knowledge identified during the phases of questionnaire development. Items remained in
the True/False and “don’t know” structure. The LKQ-R was used in the second administration of
Phase 4 (see Appendix G for Revised Version).
Analyses. The same analyses were conducted for both samples, except that item
discrimination was also conducted for the second sample. Participants completed the survey
through an online link and following data collection all responses were entered and analyzed in
the Statistical Package for the Social Science (SPSS) version 19 software (IBM Corp., 2010).
Descriptive statistics including frequencies, percentages, and measures of central tendencies
were calculated for survey items and demographic items. An alpha level of 0.05 was set to
determine the level of statistical significant.
Kruskal-Wallis One-Way ANOVA. The Kruskal-Wallis one-way analysis is used to
determine whether three or more nominal groups (e.g., close proximity, other proximity,
none/heard of SLE, deeper educational exposure, none) are the same or different on some
continuous variable of interest (e.g., scores on the LKQ or LKQ-R; Chan & Walmsley, 1997). In
order to assess any differences between educational exposure and disease proximity groups
across the LKQ the standard One-Way ANOVA analyses could not be completed because the
data were not normally distributed; therefore, this nonparametric equivalent was utilized. The
KW ranks each groups’ median score on the continuous variable (LKQ scores); thus, the groups
are ranked in order and it is provided in a mean rank ordering. Two very important advantages of
ranking data (i.e., conducting a Kruskal-Wallis) instead of using the original data are (1) the
calculations are simple and (2) few assumptions are made about the kind of distributions.
Internal Consistency. Internal consistency indicates how well the items on a measure fit
together conceptually and ensures the level of consistency of answers item by item (Terwee et
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al., 2007; Clark & Watson, 1995). The Kuder Richardson-20 Formula was used due to researcher
agreement that it is a more appropriate statistical method to calculate dichotomous items
(Wagner et al., 2005). Score values of the Kuder Richardson-20 range from 0.0 to 1.0, where a
score of .70 is the low end of an acceptable score (DeVellis, 2003).
Split-Half Reliability. A second internal consistency measure was also calculated. A splithalf reliability assesses the internal consistency of a test, by dividing the scale into two equal
parts to test equally what is being measured (Crocker & Algina, 1986). Each half of the measure
receives a Pearson r score, ranging from -1.00 to 1.00 and then each half is compared to one
another. Therefore, another internal consistency score was reported: Spearman-Brown
coefficient. The measurement procedure is considered to demonstrate split-half reliability if the
two sets of scores are highly correlated (DeVon et al., 2007).
Item difficulty. A full range of responses is important for a novel questionnaire and those
items that have limited discrepancy should be excluded. In particular, floor and ceiling effects
should be examined based on item distribution (Johnson et al., 2011). The item difficulty
analysis is conducted by dividing the number of individuals who responded correctly by the
number of total respondents. The scores are then used to identify items that are answered
correctly by more than 80% (too easy) or fewer than 20% (too difficult; Wollack, n.d; Carpenter,
et al., 2009). Values are used to assess item difficulty, values range from 0.00 to 1.00 and values
closer to 0.00 are considered more difficult (Sim & Rasiah, 2006). It is optimal to have a
difficulty level of .75 when there are two options for a test (McCowan & McCowan, 1999).
However, scores between .30 and .80 are considered acceptable.
Item discrimination. The item discrimination index is a measure of how well an item
distinguishes between respondents who are knowledgeable and those who are not (Wollack, n,d).
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This statistic measures the differences between the percentage of participants in the lower and
upper 27% of scorers who score correctly (Sim & Rasiah, 2006). Scores range from -1.0 to 1.0
and converted into a percentage. The higher the discrimination index the better the item can
determine the difference between participants who score high and those who score low on the
questionnaire (Sim & Rasiah, 2006). Scores of 0.4 and higher are considered desirable items and
a minimum of 0.2 has been proposed as the cutoff value below at which items should be
discarded (McCowan & McCowan, 1999).
Readability. All instruments used to educate individuals should not exceed a ninth grade
reading level; however, readability scores often exceed the ninth grade level (Rudd, Moeykens,
& Colton, 1999). Not exceeding a ninth grade level helps to ensure that questions can be
understood by a wider range of readers (Terwee et al., 2007). There are a variety of readability
analyses, but there is controversy about which to use because some analyses have been found to
produce different scores for the same material (Calderon, Morales, Liu, & Hays, 2006; Friedman
& Hoffman-Goetz, 2006). For the current study, readability was assessed through two common
measures. The Flesch-Kincaid Readability formula (FRF), which provides a grade reading level
score (Kincaid, Fishburne, Rogers, & Chissom, 1975). This assesses the readability of text based
on the number of syllables per word and words per sentence (Young, et al., 2002). The Flesch
Reading Ease Scale (FRES) provides an age appropriate reading level. Both scores are calculated
by using computer software in Microsoft Word (Coleman & Liau, 1975; Rhee, Von Feldt,
Schumacher, & Merkel, 2013).
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Results
Phase 1: Conducting Provider Interviews
The interviews conducted were informed by a set of items designed to represent relevant
SLE knowledge domains. Three medical providers were enrolled. The interviews took 55
minutes, 38 minutes, and 1 hours and 5 minutes, respectively.
The qualitative data presented encompass the interview data gathered from the first and
third sets of protocol questions (Appendix A). Data gathered during the second set of questions
were not relevant to the creation of the questionnaire because the purpose of set two was to
determine whether any SLE-specific questionnaire tools were used by the providers. They all
reported that no such tool existed. Under set one, I will report on the SLE-specific content that
the providers gave regarding information informed by the Common Sense Model of Illness, A)
cause, B) identity, C) timeline, D) controllability, E) consequences. For the third set of interview
items, I will briefly present data that the providers reiterated and added with regard to educating
others.
Research Question 1. What are the common topics that providers identified as being
important to be included in the Lupus Knowledge Questionnaire?
Interview Set One: Common Sense Model of Illness. Providers were asked to provide
detailed topics, themes, or general facts that related to the five dimensions of the CSM. Some of
the dimensions proved to be more difficult to provide facts or explicit concepts on due to the
dimension not having one or a simple straight forward answer. This problem was identified
throughout the interviews and it attributed to the fact that SLE is not predictable and patients
experience different disease expressions (physical complications, internal organ system
involvement) and severity of disease (flares; mild or severe). Nevertheless, results below

35

describe the range of topics that the providers give in an attempt to report clear and factual
information.
Cause. The providers reported that understanding the cause of SLE requires an awareness
of broad and narrow facts. Broadly speaking, providers reported that the cause of SLE is not
fully understood. They reported knowing about risk factors but ultimately reported that it is
difficult to identify each person’s triggers or reason for the disease onset. This is why patients
should be aware of the three categories of SLE cause. These include the involvement of genetics,
environmental hazards, and hormones all of which are areas that the medical community has
linked to SLE onset.
Beginning with genes, providers mentioned that a person has a genetic predisposition for
SLE prior to the disease actually showing symptoms. For the onset to occur individuals who
have the various genetic sequences and linkages for SLE must come in contact with an
environmental “trigger” which then activates the mutation and the signs and symptoms begin
expressing. Scientists have identified these genetic aspects of SLE. However, it is much more
difficult to identify which of the environmental or hormonal triggers initiated the disease
expression and there are no fail-proof ways of assessing what trigger will cause or has caused
each case of SLE to activate. Nevertheless, factors that have been linked to the onset of SLE
were increased exposure to sunlight, direct exposure to various hazardous chemicals, pregnancy,
and increased life stress. Hereditability is important to understand because it can allow for
someone to be aware that they have or may have the genetic predisposition for SLE.
Identity/Symptoms. The providers’ discussions regarding symptoms unanimously
supported the notion that patients need to know that the general severity of symptoms vary. Just
as the specific triggers are hard to identify for each individual patient, each person’s experience
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with symptom expression and severity are often unique to him or her. It was reiterated that being
aware that the intensity of symptom expression can help patients learn to manage their disease
better. Although severity may vary, many symptoms are quite similar. The providers included
both visible and invisible symptoms, but highlighted the increased number of invisible symptoms
that patients experience.
The providers mentioned the chronic symptoms of SLE and how more flares occur but
many internal symptoms can only be identified by test results. The providers emphasized the
extreme fatigue and chronic stiffness and joint pain that occurs. These symptoms were discussed
as the first indicators of rheumatologic conditions but the symptoms are often disregard by
patients and providers. Patients tend to wait to seek answers because they attribute their tiredness
and soreness to other stressors, concerns, or conditions. One provider mentioned that he tends to
see patients once the accumulation of symptoms already occurs. These include weight gain or
loss, hair loss, loss of circulation in the hands (causes the hands to take on a blue tint), facial skin
rashes, digestive system issues, and increased feelings of depression. These symptoms are also
often missed by medical providers because they can be common in other conditions.
The final set of symptoms that the providers discussed were the medical tests used to
confirm an SLE diagnosis. They named some commonly used diagnosis tests, which included
the antinuclear antibodies (ANA), platelet count, antibodies to double-strand DNA (anti-dna),
and antibodies to phospholipids (aPLs). These tests are not often run until a multitude of other
conditions have been ruled out. For instance, the ANA is the most commonly used diagnostic
test. However, its scores can become elevated for other reasons, thus, a high rate of false
positives and false negatives occur for patients. Therefore, a combination of these various
antibody tests and blood draws need to be run to gather enough data to confirm a diagnosis.
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In order to have a diagnosis of SLE, a patient must have a combination of the physical
symptoms and medical test results. The providers highlighted how important it is that patients
tell their doctor when they experience any physical symptoms. One provider mentioned that he
hopes patients always hold their own feelings in high regard and express to their providers when
they feel “off” because patients are the best reporters of their own experiences. He believed that
patients are ignored by their physicians too often. Therefore, in order to identify symptoms early
and begin treatment patients must be an active reporter of their experiences.
Course/Timeline. It is important for patients to understand that this is a chronic disease
and they will have it forever, but their life does not end when they receive a diagnosis. The
providers reiterated that patients need to understand that the diagnostic process is lengthy and the
timeline to receive a diagnosis varies greatly. However, two of the providers reported that they
are much more familiar with various SLE signs and symptoms than other medical professionals;
therefore, they are able to diagnose the patient earlier. They reported that many other providers
not familiar with SLE do not pay much enough attention to the accumulation of symptoms and
end up writing their patients off. All three reported this as a common concern and reason for why
the process of receiving the diagnosis is so lengthy.
As a rheumatologist, one provider receives referrals for recently diagnosed patients. He
reported having different objectives when it comes to considering an SLE timeline. His concerns
involve understanding how long the disease had been present prior to the official diagnosis
because that timeline is critical for understanding the amount of damage that has occurred.
Knowing those details informs him about what the appropriate medication regimen involves. The
earlier the treatments can begin the less damage occurs in the body. There is no “one rule fits all”
when it comes to diagnosing and treating.
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Controllability/Curability. The providers unanimously agreed that patients need to
understand that SLE is not a death sentence. The providers reported optimism in current
treatments and highlighted how the disease can be managed with treatments. In order to control
SLE, patients must know their body and how their day-to-day activities influence how they
experience their SLE. For instance, paying attention to symptoms is critical for helping control
the ebbs and flows of symptom severity. One day a patient may feel very healthy while the next
they may feel extremely sick. In order to better control their SLE patients must alter their
lifestyle to ensure they do not exert themselves too much.
Medications have been adapted over the last 20 years and the providers reported that they
have positive effects when taken correctly and consistently. Patients must understand how
important it is to know their medications and understand that some medications (e.g., steroids)
have quite harmful long term effects while other medications (e.g., anti-inflammatories) are
taken daily to ease aches and pains. Ensuring accurate adherence will help minimize severe
flares. SLE can be managed by medications but receiving the appropriate dosage is a process that
requires patient-provider collaboration and teamwork. Additionally, it is important that patients
understand that SLE is not contagious. The fear of giving it to another person is a common
misconception.
Consequences. The providers were asked to discuss how an SLE diagnosis influences a
patient’s life: socially, physically, and mentally. The providers elaborated that the majority of
their previous and current patients express a concern about the ability to “maintain their previous
life.” Patients do not want to feel limited by their diagnosis and so learning how to manage their
disease is beneficial and helps patients become more optimistic. Increasing social support helps
increase optimism, as does learning to monitor one’s physical and mental experiences. Co-
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morbid diagnoses of depression and/or anxiety after receiving an SLE diagnosis are common and
contribute to the shift in patient’s lives.
The providers mentioned how patients are often scared and confused by their diagnosis
and tend to believe that they cannot maintain their physical lifestyle. The providers agreed that
when a patient manages their SLE and participates in their treatments their life does not need to
change dramatically. However, they do warn that because of the variability of symptom severity
neither they nor a patient can be sure what each day will look like. Therefore, caution must be
taken. Even more, many patients with SLE often end up being unable to work.
To ensure that a patient’s SLE is managed, he or she must monitor their lifestyle.
Common topics related to lifestyle management included maintaining a moderately active
lifestyle (e.g., nonaerobic), incorporating healthy diet (e.g., minimize meat and gluten), minimize
prolonged sun exposure, no smoking, and correct medication management. Looking towards
one’s future and being aware of his or her increased risk of comorbid diagnoses is an additional
reason that proper lifestyle management needs to occur. Prolonged SLE consequences are quite
severe and include neurological concerns (e.g., memory), digestion issues, cardiovascular health,
and circulatory function.
Interview Set Three: Additional Information for Others. During set three, providers
were asked to report on what information related to SLE was important for other people (e.g.,
family, friends, social supports, general public) to know. The goal was not only to gain
information about SLE facts relevant for patients but also to know if additional aspects of SLE
knowledge were important for others to know about SLE. The emphasis in this section was to
encourage the providers to give any reiteration of themes already mentioned and to allow for
further elaboration.
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General Information for Others. Overall, the providers reiterated many similar themes
that they had mentioned during set one. The providers discussed that a portion of distress patients
experience occurs because of others being misinformed and uneducated about SLE. Therefore, it
is important to help educate family and supporters about SLE. Providers discussed noticing that
those who interact with patients are just as scared and confused as patients are of the
complexities of SLE. Increasing awareness of SLE and how it is experienced might be the first
step in helping create an educated support network for patients.
Specific for Family. When it comes to educating the family members, it is more important
to understand who the patient wants involved in their care rather than presuming who is
important to inform. This is because support is not unidimensional and patients may bring their
spouse, child, parent, or friend with to a doctor’s appointment. Thus, increasing the awareness
and knowledge that those individuals have of SLE should take priority. This is important to
understand because these support individuals are in the appointment with patients when the
doctor explains any concerns or results. That supporter should be able to remain active and
involved in the appointment alongside the patient. This means having a thorough understanding
of SLE. This is an additional way to encourage better collaborative communication between all
parties. One provider said that he believes patients have so much on their mind that having an
informed supporter with them is essential.
Two phrases that the providers mentioned as being unwarranted misconceptions about
SLE were “it’s all in their head” and “…but you look fine.” These two phrases relate to the
invisibility of SLE and therefore other people are unable to see the effects of SLE. SLE is a
disease and it is not “in their head.” If SLE manifested on the outward appearance people might
begin to understand how detrimental it is on the person. However, because people cannot see the
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internal deterioration of SLE they use this phrase. Phrases such as these belittle and minimize the
realities of SLE. Patients need to know that these phrases are false and it is equally important that
family and the public understand that although symptoms are not seen, they are felt. Providers
reiterated how often family and friends of SLE patients believe that the patient is crying wolf or
exaggerating to receive pity. This misconception about invisible illness is a major downfall in
creating a supportive environment for patients. Therefore, increasing others’ awareness that even
though the patient may look okay on the outside their internal body is not okay.
Specific for General Public. The providers were aware that this measure would be used to
assess two general public samples’ knowledge of SLE and thus they were asked if they had
different considerations about how to increase community knowledge. They all agreed that this
goal is ambitious and hopefully one day we can say that the public is aware and knowledgeable
but that is far in the future. One provider mentioned that the best hope we have for informing the
public is to educate the public about invisible diseases overall, not just SLE. The general
comment regarding educating the public is to understand that this illness is not a death sentence
and that it is not contagious, which are two common misconceptions that increase the stigma
surrounding SLE.
Phase 2: Reviewing Patient Education and Interview Data
Creating the LKQ Items. For the draft version of the LKQ, the items’ content had been
chosen if such content had been brought up during the interviews with the medical providers
and/or if the SLE facts were in the LFA’s packets (DeVon, et al., 2007). There is a wide range of
important SLE facts that were identified by the providers. Therefore, to ensure that the LKQ
could be used as a general knowledge tool and not contain highly specific and jargon information
the content was chosen selectively. For example, the providers discussed various details
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regarding medication regimens that would be important for patients to know, but not necessary
for the community to know.
Conducting Directed Content Analysis. The Common Sense Model of Illness (CSM)
was used to guide the theoretical foundation of the present study. In order to inform the LKQ, the
dimensions of the CSM (identity, cause, timeline, controllability/curability, consequence) were
used to generate items. For example, the draft version of the LKQ contained 38 items and of
those items, 13 were coded as cause. Nine items were coded into the consequence dimension;
eight items were coded as curability/controllability, seven items were coded for identity, and
three items were in the timeline dimension. (See Appendix E for LKQ and CSM.)
Phase 3: Verifying and Revising LKQ Draft.
The draft version of the LKQ was created, verified by providers and tested for various
item analyses (e.g., readability and item difficulty). Those results are described below. Edits
from such revisions were applied to the revised version of the LKQ, which was administered to
the second community sample.
Readability. For the draft version of the LKQ, the Flesch-Kincaid grade level or FRES
score was 8.9, which indicated a ninth grade reading level. The overall scale was grade
appropriate (Rudd, Moeykens, & Colton, 1999; Terwee et al., 2007). However, one item maxed
out at 16.5 (lupus increases an individual’s risk of premature cardiovascular disease (heart
disease)), but others were as low as a second grade reading level (Hair loss in a symptom of
lupus, 2.3). For the Flesch-Kincaid readability formula (FRF) the score was 49.0 which is
considered “very difficult” (Friedman & Hoffman-Goetz, 2006). The scores ranged from 10.5
(bipolar disorder is the most common co-occurring mental health diagnosis) to 95.9 (lupus is
caused by the same virus that is linked to HIV); see Table 6 for full item difficulty scores.
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Overall, the grade level score of the draft version satisfied the recommended grade level
readability.
Content Verification. After the survey was drafted, the three medical providers were
asked to verify the content of the draft version and provide feedback regarding item accuracy and
clarity. For the draft version of the LKQ, items were created based on the content analysis from
phase two. All of the results follow; to see which items were retained or excluded based off
various analysis methods refer to Appendix D.
Content Validity Index. The providers were asked to provide relevance ratings on the
Content Validity Index (CVI) for each item of the LKQ-draft (1= not relevant, 4= highly
relevant) and provide any additional feedback. A rating of three or four indicated the content was
perceived as valid and consistent with the conceptual framework of general SLE knowledge,
whereas, items rated one or two were considered irrelevant and unnecessary, unless, the
providers gave accuracy feedback (Lynn, 1996). Items that were deemed irrelevant (CVI score
of 1 or 2) were deleted unless a provider gave written feedback, the feedback was intended to
create a relevant item. The items with feedback were edited and retained for the revised version.
The items that were deemed relevant (CVI score of 3 or 4) were retained. An item score of .80
(4/5 providers) has been cited for being on the low end of acceptability for item retention (Lynn,
1986); however, researchers have indicated that a score of .67 (2/3 providers) is acceptable
(Polit, Beck, & Owen, 2007). Therefore, if at least two of the providers gave a score of 3 or 4,
that item was retained. There were two expectations. Items number 6 and 21 on the draft version
were excluded from the revised version due to my subjective opinion of making cuts to the
length of the questionnaire and because both are relative for the patient and potentially tap into
perceptions of SLE rather than strict knowledge.
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All three providers agreed that two of the items were not relevant (score of 1 or 2). Eleven
items were unanimously agreed upon as is as being relevant (score of 3 or 4). Provider 1
provided additional comments for 13 of the 38 items, provider 2 provided comments for 9 of the
38 items, and provider 3 opted to give no written feedback. Of the 38 items that were included on
draft LKQ, 28 items were edited for clarity or accuracy (See Appendix D: Verification Feedback
from Providers). At the end of the verification process, the l I-CVI scores ranged from 1.00 (3/3
agreement) to 0.00 (0/3 agreement).
Regression Analysis. A regression analysis was used to test which of the 38 items of the
LKQ accounted for the most predictive value for LKQ scores. The 38 items were analyzed
within a forward regression analysis and the analysis indicated that thirteen items explained 92%
of the variance (R2=.920, F (1,322) = 5.270, p = .022) of the knowledge scores. Those thirteen
items significantly predicted the overall score on the LKQ. These data contributed to the decision
to keep various items because the items’ associations with predicting participants who scored
better on the LKQ. Additionally, the data from the regression analysis further supported the
results from the CVI. The regression analysis results can be found in Table 5.
Item Difficulty. In addition to the items retained based on the CVI and regression
analysis data, three more items were retained from the draft version to the revised version
because of my subjective reasoning and the exploratory item difficulty scores they received. Item
number 36 (bipolar), 38 (Caucasian more than others), and 17 (jaundice) were kept because
during the exploratory item analysis (discussed below) these three items results in more
appropriate difficulty scores due to better distributions of true and false responses. Therefore,
these items were considered key items that were not too easy, but also not too difficult.
Additionally, all three of these items incorporate concepts that were directly related to what the
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providers discussed and information mentioned in the pamphlets. Together, these two reasons
warranted enough support to add them to the revised version to further assess their value as LKQ
items. To see each item’s difficulty score, see Table 6.
Phase 4: Testing the LKQ and LKQ-R
Community Sample 1. The LKQ was administered to the first community sample. The
results of the first administration of the LKQ are presented below.
Demographic. There were a total of 345 young adults screened from a community
sample to be included in the first administration of the LKQ. However, seven participants’ data
were excluded because they omitted all 38 items on the LKQ. The final sample size included a
total of 336 participants. The assumption of normality was assessed using the recommended
Shapiro-Wilk test to determine if the LKQ scores were normally distributed (Ghasemi &
Zahediasl, 2012). The first sample was reviewed based on the Shapiro-Wilk (SW=.743, df=336,
p > .001), skewness (1.301), and kurtosis (.562) and the findings suggested that the normality
assumption was not met. Therefore, nonparametric analyses were used.
Research Question 2. How do participants in a community sample (the young adult)
score on the LKQ?
Lupus Knowledge Questionnaire. The draft version of the LKQ contained 38 items that
assessed general SLE knowledge. Data from the 336 participants were examined to determine
the level of knowledge the participants had of SLE. Overall, 160 participants (47.6%) scored a
zero on the LKQ. The average score on the LKQ was 16.34% (SD= 23.07%) and scores ranged
from 0% to 92% (Figure 1: LKQ-draft Scores). No participant answered all 38-items correctly.
Two participants scored the highest with a 92% or 35/38 items answered correctly. Only 45
participants scored a 50% or higher on the LKQ (13.4%) and 155 (46.1%) participants indicated
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having no knowledge of SLE by choosing “don’t know” for all 38 items. The majority of the
participants reported, “don’t know” for all items (Table 7: response rates for each draft item).
The first sample administration of the LKQ exhibited good internal consistency (Kuder
Richardson-20 = .960). Items were coded as 0 and 1’s, in that correctly answered items incurred
a coding of 1, while both incorrectly answered and “don’t know” responses were coded as 0.
Split-half reliability was also conducted and exhibited an excellent reliability score (SpearmanBrown =.931)
Item Difficulty. Item difficulty analyses were calculated for each item. Each score is
represented by a value, ranging from 0 to 1.00. The closer an item’s score is to 1.00 indicates that
more participants answered the item correctly while scores closer to 0.00 were answered
correctly by fewer participants. Item difficulty scores varied for each item based on the number
of responses accounted for. For the 38 items, item difficulty scores ranged from 0.027 to 0.298.
As referenced previously, scores ranging between .3 and .8 are ideal (McCowan & McCowan,
1999). Therefore, scores were unanimously indicative of a very difficult questionnaire. However,
due to the high degree of “don’t know” responses the low scores were expected. The item
difficulty scores for each item are presented in Table 6.
An exploratory item difficulty analysis was also conducted to gain perspective of the
items without the high rate of “don’t knows.” Scores were calculated by accounting for
participants who responded with either true or false (i.e. those who felt confident in their
knowledge and attempted the answer the item) without accounting for the “don’t know”
responses. For the 38 items, the exploratory item difficulty scores ranged from 0.283 to 0.971.
The purpose of exploring these scores was to assess the hypothesized item difficulty scores that
may have been more appropriate with a sample that would have been more knowledgeable.
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Item Discrimination. Due to the skewed scores of the entire sample (almost half of the
participants received a score of zero), item discrimination could not be calculated. The item
discrimination scores would traditionally be calculated when wanting to identify which items can
discriminate between overall scores of respondents who did well and those who did not. For
example, to assess each item’s discrimination value, the percent score of the item that was
attained by the top 27% would be subtracted from the percent score of the percent score attained
by the lower 27% of the participants who answered that item. Therefore, the equation would look
similar to this, 16% - 0% = 16%. This sort of discrimination score indicates that the item is
unacceptable (Sim & Rasiah, 2006).
Educational Exposure to SLE. Participants were asked to report their current level of
educational exposure to SLE. When asked whether the participants had heard of SLE, the large
majority reported yes (N=245, 72.49%). However, when asked about their further exposure to
the disease, affirmative responses diminished greatly. When participants were asked had they
read about SLE, learned about SLE in a class, or attended a lecture on SLE the large majority
reported no for all three, respectively (N=272, 80.47%; N=293, 86.43%; N=331, 97.93%).
Disease Proximity to SLE. Participants were asked to report any disease proximity to
SLE by indicating if they had a personal diagnosis, a family member (immediate or extended)
diagnosed and/or if they knew any other person living with SLE. If they reported “yes” they
were asked to identify the relationship of that individual (e.g., friend, neighbor, mother-in-law).
Participants were given the option to not respond to these items without repercussions. Of the
328 who replied when asked about a personal diagnosis, only three participants reported
personally having a diagnosis of SLE (0.09%) and twenty-two reported knowing a family
member (immediate=8; 2.4%, extended=14; 4.6%) who has a diagnosis. An additional 34
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participants reported knowing some other person with an SLE diagnosis (10.4%; Table 2:
Disease Proximity Frequency).
Perceptions of Knowledge. Participants were asked to report on how confident they were
of their current accuracy of SLE knowledge prior to taking the LKQ. Only seven participants
reported feeling “confident” in their knowledge and an additional five felt “extremely confident,”
totaling only 3.6% of the sample. The remaining 323 participants reported either no confidence,
some confidence or that they were unsure (N=238, 70.8%; N=49, 14.6%; N=36, 10.7%,
respectively).
Participants were also asked to report how they perceived their own knowledge of SLE
compared to the average person. Only a total of 8% of the sample believed they had more
knowledge of SLE than the average person (Much More Knowledge = 5; More Knowledge= 22).
Ninety-one participants reported having less knowledge than the average person (27.1%). The
highest group reported that they had much less knowledge about SLE than the average person
(N=114, 33.9%). The rest reported believing they had the same level of knowledge as the average
person (N=101, 30.1%). Overall, people believed they had less knowledge of SLE than the
average person.
Hypothesis 1. Individuals with educational exposure to SLE will have higher scores on
the LKQ than those who have no exposure to SLE.
A Kruskal-Wallis one-way ANOVA was conducted to assess rank differences between
the educational exposure groups. Group 1 consisted of participants who had heard of SLE
(N=160), group 2 consisted of those who had endorsed at least one of the other exposure items
(read about SLE, attended lecture, and/or read about it; N=86), and group 3 consisted of those
who had reported having none of the above educational exposures (N = 89). Results indicated
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that there was a statistically significant difference in LKQ scores earned by those with different
educational exposure, χ2(2) = 96.12, p < .001, with a mean rank of 169.85 for group 1, 235.25 for
group 2, and 99.69 for group 3.
A post hoc sums test indicated that participants who reported having heard of SLE (group
1; 105.45) scored significantly lower on the LKQ than those who had had a deeper educational
experience (group 2; 157.16), χ2(1) = 30.83, p < .001. Secondly, participants who reported
having learned about it in a deeper educational experience (group 2; 122.51) scored significantly
higher on the LKQ than those who reported no educational exposure (group 3; 56.01), χ2(1) =
30.83, p < .001. Similarly, individuals who had heard of SLE (group 1; 145.73) scored
significantly higher on the LKQ than those who reported no educational exposure (group 3;
89.54), χ2 (1) = 43.22, p < .001.
Hypothesis 2. Individuals who have closer proximity to SLE will have higher scores on
the LKQ than those who indicate having no proximity to SLE.
A Kruskal-Wallis one-way ANOVA analysis was conducted to assess rank differences
between the disease proximity groups. Group 1 consisted of those who self-identified as having
SLE and/or indicated an immediate or extended family member had SLE (N=22). Group 2
consisted of those who indicated that they knew someone else with SLE (N=29). Group 3
consisted of people who reported that they knew no one with SLE (N=276). Results indicated
that there was a statistically significant difference in LKQ scores earned by those with different
disease proximity, χ2 (2) = 36.23, p < .000, with a mean rank of 245.84 for group 1, 222.40 for
group 2, and 151.34 for group 3.
A post hoc rank sums test indicated that participants who reported having close proximity
(group 1; 27.84) did not statistically differ from those who reported knowing someone else with
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SLE (group 2; 24.60), χ2 (1) = 0.60, p = .440. However, those with close proximity to SLE
(group 1; 229.50) compared to those with no proximity (group 3; 143.12) scored significantly
higher on the LKQ, χ2 (1) = 23.28, p < .001. Similarly, those with other proximity (group 2;
212.79) compared to those with no proximity (group 3; 146.72) also scored significantly better
on the LKQ, χ2 (1) = 16.78, p < .001.
Community Sample 2:
Demographic. The final sample size for the administration of the LKQ-R was 188
participants because those participants correctly answered the validity item. The assumption of
normality was assessed using the recommended Shapiro-Wilk test (Ghasemi & Zahediasl, 2012).
The second sample was reviewed based on the Shapiro-Wilk (SW=.743, df=336, p > .001),
skewness (1.301), and kurtosis (.562) the findings suggested that the assumption of normality
was not met. Therefore, nonparametric analyses were used.
Research Question 2. How do participants in a second adult community sample score on
the LKQ-R?
Lupus Knowledge Questionnaire-Revised. The revised version of the LKQ used in the
second sample contained 34 items. Of the 188 participants, no one received a score of zero.
Seventeen participants received a score of 3% by getting 1/34 items correctly (9.0%). The
average score on the revised version was 41.16% (SD= 22.80%) and scores ranged from 3% to
94%. Overall, no participant answered all 34 items correctly. Only one participant scored the
highest with a 94% or 32/34 items answered correctly. Seventy-five participants scored a 50% or
higher on the LKQ-R (39.89%). Figure 2 provides a pie chart of the LKQ average range scores
for the second sample (see Table 13: LKQ-R Response Rates). For the revised version of the
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LKQ, items were retained based on CVI scores, a regression analysis, and information gathered
through the item difficulty analysis.
The LKQ-R exhibited good internal consistency (Kuder Richardson-20 = .940). Items
were coded as 0 and 1’s, in that correctly answered items incurred a coding of 1, while both
incorrectly answered and “don’t know” responses were coded as zero. Split-half reliability was
also run and exhibited good reliability (Spearman-Brown Coefficient= .889).
Participants were asked whether they had educational exposure and disease proximity.
Therefore, in order to assess if those who reported educational exposure also more commonly
reported disease proximity a chi-square analysis was conducted. The analysis indicated that there
was a statistically significant association between those who identified as having proximity to
SLE and those who identified having educational exposure to SLE, X(6)=14.988, p =.0.020. The
Phi value (.284, p=0.020) indicates a medium strength association.
Readability. For the final version, the overall Flesch-Kincaid grade level or FRES score
was 8.7, indicating a near ninth grade reading level, which is appropriate (Rudd, Moeykens, &
Colton, 1999; Terwee et al., 2007). The score range for individual items decreased after edits
occurred for the revised version to be between a score of 3.6 (treatment can cure lupus) 13.9
(bipolar disorder is the most common co-occurring mental health diagnosis for lupus patients).
For the Flesch-Kincaid readability formula (FRF), scores range from 0 (very difficult) to 100
(very easy). The score scale’s score was 49.6, which is considered difficult (Friedman &
Hoffman-Goetz, 2006). The scores ranged from 17.9 (bipolar disorder is the most common cooccurring mental health diagnosis for lupus patients) to 82.3 (hair loss/thinning is a symptom of
lupus); see Table 12 for item’s score. Overall, changes on the FRES and FRF slightly improved.
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Certain items that contained more jargon language (e.g., cardiovascular disease, bipolar,
co-occurring) incurred higher ratings of difficulty, which increased the score. Items were not
deleted based on their FRES or FRF score because some items were in the appropriate range for
one or the other score (e.g. either reading ease or grade level). Additionally, previous researchers
have had items that exceed the aimed score, but because their overall score remained appropriate
the items were retained but incorporated further explanations (e.g., heart disease and explaining
genetic predisposition; Rhee et al., 2013).
Item Difficulty. Item difficulty was calculated for each item. Each score is represented by
a value ranging from 0 to 1.00. The closer the score was to 1.00 the more participants answered
the item correctly and items with a score closer to 0.00 were answered correctly by fewer
participants. Item difficulty scores ranged from 0.048 (item 23, immune count test) to 0.711
(item 25, immune system weakened). Even though item 20 revised a score of 1.00, it was not
included in the difficulty range, because this item was used as the validity item and everyone
included answered that item correctly. The item difficulty scores for each item of the revised
version are presented in Table 12.
Item Discrimination. For the second sample, scores were more variable without the
influx of don’t knows and zeros and therefore, item discrimination was calculated. The higher
the discrimination index the better the item can determine the difference between participants
who score high and those who score low on the questionnaire (Sim & Rasiah, 2006). Scores of
.40 and higher are considered desirable (McCowan & McCowan, 1999). Items on the revised
version were calculated for item discrimination by computing the differences between the top 51
participants and the bottom scoring 51 participants (top and bottom 27%). Discrimination scores
ranged from 11.7% to 85.1%. Only three of the 34 items received an “unacceptable” score (item
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23,30,32); however, these items provided insight for what presumptions are believed by many
community members. For this reason, they should be retained for further examinations of the
efficacy of the LKQ-R (see Table 12).
Educational Exposure to SLE. Participants were asked to report their current level of
educational exposure to SLE. When asked whether participants had heard of SLE, the large
majority reported yes (N=179, 95.2%). Almost half the sample reported having read about SLE
(N=84, 44.7%). However, only six participants reported having attended a lecture on SLE
(3.2%). Finally, 24 participants reported having learned about SLE in a class (12.8%; see Table
11: Educational Exposure Frequency).
Proximity to SLE. Participants were asked to report on their proximity to SLE. The
participants were asked to report on a personal diagnosis, a family member diagnosis and/or any
other person they know diagnosed with SLE. If they identified a person, they were asked to
describe the relationship of the individual. Participants were given the option to not respond to
the following items without being penalized. Of the 188 participants who were included in the
final analyses, 186 participants opted to reply to the disease proximity items. When asked about
a personal diagnosis, three participants reported having a diagnosis of SLE (1.6%) and twentytwo reported having a family member (immediate= 4, 2.1%, extended=18, 9.6%) diagnosed. An
additional 48 participants reported knowing some other person with SLE (25.5%; see Table 9:
Disease Proximity Frequency).
Perception of Knowledge. Prior to taking the LKQ-R, participants were asked how
confident they were of their SLE knowledge. Only ten participants (5.3%) reported feeling
confident in their knowledge and just one participant reported feeling extremely confident,
together accounting for 5.8% of the sample. Half of the sample reported having no confidence in
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their knowledge (N=94, 50.0%). While another 25% of the sample reported having some
confidence (N=47). The remaining participants reported being unsure about their knowledge of
SLE (N=36, 19.1%).
Following the LKQ-R, participants were asked to report on how they believe their level
of knowledge compared to the average person. Almost half of the sample reported having the
same knowledge that the average person has (N=92, 48.9%). A total of 59 participants reported
having less knowledge (N=33, 17.6%) or much less knowledge (N=26, 13.8%) than the average
person. However, 37 participants reported feeling as though they had more knowledge (N=31,
16.5%) or much more knowledge (N=6, 3.2%) than the average person.
Hypothesis 1. Individuals with educational exposure to SLE will have higher scores on
the LKQ than those who have no exposure to SLE.
A Kruskal-Wallis one-way ANOVA was conducted to assess the relationship between
LKQ-R scores and participants’ educational exposure. Group one consisted of those who had
heard of SLE (N=93), group 2 consisted of those who had endorsed at least one of the other
exposure items (read about SLE, attended lecture, and/or read about it; N=85), and group 3
consisted of those who had reported having none of the above educational exposures (N = 9).
Results indicated that there was a statistically significant difference in LKQ scores earned by
those with different educational exposures χ2(2) = 47.09, p < .001, with a mean rank of 68.51 for
group 1, 123.66 for group 2, and 77.33 for group 3.
A post hoc sums test indicated that participants who reported having a deeper educational
experience with SLE (group 2; 116.75) scored significantly higher on the LKQ than those who
had only heard of SLE (group 1; 64.59), χ2 (1) = 45.59, p < .001. Additionally, participants who
reported having learned about SLE in a deeper educational experience (group 2; 49.91) scored
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significantly higher on the LKQ than those who reported no educational exposure (group 3;
24.78), χ2 (1) = 6.92, p =.009. However, the LKQ scores for individuals who had heard of SLE
(group 1; 50.91) did not differ significantly compared to those who reported no educational
exposure (group 3; 57.56), χ2 (1) = 0.42, p =.519.
Hypothesis 2. Individuals who have closer proximity to SLE will score higher on the
LKQ than those who indicate having no proximity to SLE.
A Kruskal-Wallis one-way ANOVA was completed to assess the relationship between
LKQ-R scores and disease proximity. Group 1 consisted of those who endorsed having a
personal SLE diagnosis and/or those who indicated having a family member (immediate or
extended) with SLE (N=21). Group 2 consisted of those who indicated that they knew someone
else with SLE (N=43). Group 3 consisted of people who reported that they knew no one with
SLE (N=122). Results indicated that there was a statistically significant difference in LKQ scores
earned by those in different disease proximity groups, χ2 (2) = 16.044, p < .001, with a mean rank
of 124.40 for group 1, 109.80 for group 2, and 82.43 for group 3.
A post hoc rank sums test indicated that participants who reported having a close
proximity (group 1; 36.31) did not statistically differ between those who reported knowing
someone else with SLE (group 2; 30.64), χ2 (1) = 1.312, p = .252. However, both group 1 and
group 2 scored significantly higher on the LKQ than those who indicated knowing no one with
SLE. Those in the close proximity group (group 1; 99.10) compared to those who reported no
proximity to SLE (group 3; 67.34) scored significantly higher on the LKQ, χ2 (1) = 10.55, p =
001. Similarly, those who reported knowing someone else with SLE (group 2; 101.16) compared
to participants who reported knowing no one with SLE (group 3; 76.60) scored significantly
higher on the LKQ, χ2 (1) = 8.421, p =.004.
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Discussion
The purpose of this study was to 1) create a novel SLE disease-specific knowledge
questionnaire and 2) assess the knowledge of community members using the LKQ. The specific
hypotheses were created to assess whether having learned about SLE in an educational setting
(i.e., educational exposure) as well as the effects of knowing about SLE on a more personal level
(i.e., disease proximity) were related to scores on the knowledge questionnaire. A four-phase
design was used to execute the study; the initial three phases involved the foundational work of
creating the SLE knowledge questionnaire and the final phase consisted of administering the
LKQ to two unique samples. Hypothesis one was supported: those with deeper educational
exposure to SLE earned a higher score on the LKQ than those with no exposure. Hypothesis two
was also supported: those with closer disease proximity to SLE earned a higher score on the
LKQ than those with no proximity. Further findings also emerged and are reviewed below.
Results of Research Question 1
In order to create a medically accurate knowledge questionnaire interviews with medical
provider were used. The interviews were the foundation of research question 1, which was to
determine what topics related to SLE medical providers believed were important to be included
in the novel Lupus Knowledge Questionnaire.
Understanding the experience of a chronic illness involves understanding that illness is a
complex process where disease-specific information is constantly being added, subtracted and
adapted throughout the life (Hale, Treharne, & Kitas, 2007). Just as the providers reflected,
understanding the experience of SLE is not unidimensional. Thus, the Common Sense Model of
Illness was chosen as the theoretical framework to support the interviews because of its
supported of the comprehensive evaluation of the dimensions of life with a chronic illness
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(Cause, Identity, Timeline, Controllability/Curability, Consequence; Diefenbach & Leventhal,
1996; Hagger & Orbell, 2003).
Responses related to the cause of SLE involved mention of the involvement of genetics,
environmental hazards, and hormones all of which have been linked to the onset of SLE (Sestak
et al., 2007; Marengo et al., 2012; Crampton, Morawski, & Bolland, 2014). Although not all
trigger factors have been identified, many known risk factors include exposure to sunlight, direct
exposure to various hazardous chemicals, pregnancy, and increased life stress.
Discussions of the identity (i.e., symptoms) of SLE involved mention that each case looks
differently, so although many symptoms are common the variability of experience between each
SLE case varies between mild and severe, which has been substantiated in previous work
assessing SLE (Sutanto et al., 2013) A number of symptoms linked to SLE that the providers
mentioned, including invisible and visible. The course or timeline of SLE resulted in some
variability in answers from the providers because the disease can be difficult to identify and
diagnose. The repercussions of the lengthy diagnostic process and how important it is that
treatments are started early is important for having a more controlled disease (Giffords, 2003).
Understanding SLE involves recognizing that the disease is controllable, but not curable.
SLE is a chronic condition; however, due to medical advances, it is much more manageable.
Two common misconceptions that the providers discussed were that SLE is a death sentence and
that it can be caught (e.g., sexually or through saliva). Previous research has indicated that some
reasons that patients do not adhere are because they have a decreased perception of the necessity
of medication use, belief that other non-medical treatments are better, and do not have a clear
understanding of the importance of the medication for SLE treatment (Carder, Vuckovic, &
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Green, 2003; Chambers et al., 2009; Harrold & Andrade, 2009; Williams, Manias, & Walker,
2008). Understanding how SLE occurs is again important for understanding how to control it.
The consequence informed the understanding of how patients work to understand and
adapt their life to understand how to now live with their disease. SLE has the potential to
influence physical well-being as well as social and mental well-being (Kool et al., 2010; Kool &
Geenen, 2012). Patients also are at increased risk of comorbid diagnoses, both mental (e.g.,
depression, anxiety; Nery et al.,2008; Bachen et al.,2009) and physical (e.g. fibromyalgia; Lam
& Petri, 2005). Therefore, patients must involve a high level of symptoms monitoring, which
becomes one of the main objectives after a diagnosis is received (Lam & Petri, 2005).
Management of daily activities and specific health behaviors were mentioned by the providers as
being important. These behaviors included maintaining a moderately active lifestyle (e.g.,
nonaerobic), incorporating a healthy diet, avoiding prolonged sun exposure, quitting smoking,
and practicing correct medication management. Practicing these modifications minimize the
severity of SLE symptoms as well as minimize the likelihood of further disease consequences
(e.g., neurological concerns, heart disease (Parrondo, 2011; Lam & Petri, 2005).
The majority of the interview time was spent discussing topics related to the needs of
patients; a portion of time was spent discussing what family, friends, social supporters, and the
general public should know about SLE. Many of the topics mentioned previously were reiterated
as being important for these other individuals. Especially supporters, people who interact with
patients daily or who accompany patients to office visits should be knowledgeable of SLE. The
knowledgeable support of a family member or spouse has been found to ease the worries that
patients have when visiting doctors (Karlson et al., 2004). Just as there were two common
misconceptions mentioned that newly diagnosed patients often report, two misconceptions that
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need to be eliminated for supporters and the public’s repertoire are: “it’s all in your head” and
“…but you look fine.” These misconceptions diminish the experience of SLE for the patient’s
daily life and perpetuate the negative stigma that is associated with invisible illness.
Results of Research Question 2
Phase 4 consisted of determining how participants scored on the LKQ, which provided
initial psychometric data for the LKQ. Two samples worth of data were collected, with one
sample being administered the draft version of the LKQ and the second sample was administered
a revised version.
The results gathered from sample one became influential learning steps that informed the
creation of the revised version used in sample two. The information learned through the item
analyses indicated that the scale had good reliability, which is essential for laying the foundation
for a new measure to be trusted. However, item difficulty scores were low and indicative of
extremely difficult items. Even more, item discrimination was not conducted because of the
inappropriate representation of knowledge from the sample. Item analyses, although resulted
with values the trustworthiness of the values is called into question. Overall, the findings from
sample one’s examination of the LKQ and the results of the content validity index feedback, the
regression analysis, and the item analyses informed the revised version.
Participants in sample one scored quite poorly on the LKQ with only averaging about a
16%, largely contributable to the 46% of participants who choose all “don’t knows.” The large
number of participants who scored zero skewed the overall samples interpretation values.
Therefore, after recognizing this influx in don’t know response a validity item was used in
sample two. Overall, sample one’s scores were likely influenced by three concerns; 1) the sample
consisted of young adults which often times results in lack of attention to the questionnaire; 2)
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the large majority of don’t know responses skewed the overall scores; 3) there was no validity
item in sample one. Therefore, the results gathered in sample one are not as reliable as sample
two’s results. Although the results of sample one were not as trustworthy, the findings were
informative of how to make improvements for sample two.
Identifying the challenges and results from sample one helped inform revisions that
improved the LKQ-R. A weakness in the design from sample one was that there was no way to
exclude for participants who did not provide full effort in responding to the knowledge
questionnaire. Therefore, the addition of the validity item improved the trustworthiness of the
data from the second sample. This can be evident because the item difficulty scores were almost
all exclusively in the appropriate range as were the item discrimination scores. The
improvements to the LKQ-R resulted in more appropriate analyses. Together, these findings
suggest that the revisions made to the LKQ to create the LKQ-R improved the overall clarity of
the results. An alternative explanation is that the participants had increased familiarly with SLE
and were able to exhibit a better range of knowledge. Further assessment of the questionnaire
should continue.
Overall, the inclusion of a validity item on the LKQ-R was likely the most influential edit
that occurred. One criticism of having a True, False, and Don’t Know response format is that
participants can receive an “out” by choosing all don’t know and thus, they choose only don’t
knows (Beatty & Herrmann, 1995). The validity item allowed for me to be able to identify those
individuals who did not provide their full attention to the questionnaire and used the don’t know
option as an “out.” The scores on the revised LKQ increased, with an average score of about
41%. The results indicated that a positive shift towards better scores occurred over the two
studies.
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To supplement the focus of the current study and explore participants’ performance on
the LKQ and LKQ-R they were asked to rate their pre- and post- test perceptions of their SLE
knowledge. The majority of both samples’ participants reported having no confidence in their
knowledge of SLE (70%, sample 1; 50%, sample 2). Participants from both community samples
were quite open about having limited knowledge of SLE. Overall, the majority of participants
rated closer to the not confident end of the scale than towards the confident end. Additionally,
after completing the questionnaires, participants were asked to compare their knowledge of SLE
to the average person. Almost 50% of the second sample reported having the same level of
knowledge as an average person. Overall, the second sample showed an increase in having more
knowledge and much more knowledge than the average person and fewer people reported having
less knowledge and much less knowledge than the average person. This may reflect the
trustworthiness of sample two over sample one. The age difference between the samples (i.e., an
average age of 21.5 in sample 1 compared with an average age of 33 in sample 2) might
represent differences in maturity and life experience. These factors, in turn, could have
accounted for some of the differences in knowledge. Of course, these hypotheses were not
evaluated within the context of this particular study.
Based on the results from the current study the average level of SLE knowledge is quite
low. However, since no study has examined SLE knowledge among community members there
was previously no known rate of SLE knowledge. Therefore, understanding the perceived level
of knowledge and identifying the average LKQ and LKQ-R scores allows for the opportunity to
explore and develop advocacy efforts aimed at increasing accurate knowledge. The average
persons’ knowledge, based on findings from this study and the questionnaires, indicates that
knowledge is likely somewhere between 16% and 41%. Even more, participants believed they
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had much lower knowledge compared to the average person. Together these indicate that
community members are confidently unaware of SLE. This low level of SLE knowledge and
perceptions of knowledge among the community is why this area of research is important. Being
misinformed about SLE has negative repercussions for the SLE community, such that, being
unaware of SLE could likely result in increased stigmatization of patients.
Results of Hypothesis 1
Hypothesis 1 was supported; individuals who reported having educational exposure to
SLE scored significantly higher on the LKQ than those who reported no exposure.
Rates of Educational Exposure. For the first community sample, 72% had heard of SLE.
However, any deeper level of educational exposure was quite rare with 80% of the sample
reporting having never read about SLE. For the second community sample, even more of the
sample (95%) had heard of SLE. All other levels of educational exposure were again, quite low.
These results indicated that having heard of SLE was quite common; however, reports of having
opportunities to learn more about SLE through deeper educational means decreased drastically.
Sample One. During the examination of hypothesis one, the three comparison analyses
conducted indicated that there were significant differences among the educational exposure
groups. Participants who reported having only heard of SLE were compared to those who
reported having a deeper educational experience with SLE. The presumption was that having a
deeper learning experience of SLE would mean that a person was able to understand SLE at a
deeper level compared to those who had only heard of SLE. The findings of this analysis
indicated that having heard of SLE held no significance when it comes to being knowledgeable
about the disease mechanism of SLE.
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The deeper educational exposure group was compared to those who reported no
educational exposure to SLE. Although this may seem like a simple assumption because no
study had examined SLE knowledge among community members with a questionnaire there had
never been a way to examine the relationship between educational exposure and knowledge.
Therefore, although these findings may be viewed as common sense, the examination and
findings related to the relationship between educational exposure and LKQ scores were novel.
Lastly, those who reported having heard of SLE scored significantly higher on the LKQ than
those who reported having no educational exposure to SLE. The result indicates that for this
sample having heard of SLE did relate to having higher scores of knowledge when compared to
those who reported no educational exposure. However, due to sample one’s skewed scores, the
result that hearing of SLE is associated with higher knowledge scores should be interpreted with
caution. Rather, the findings and conclusions drawn from sample two appear to provide more
trustworthy results.
Sample Two. During the examination of hypothesis one for the LKQ-R, the analyses
indicated that there was a significant difference among the groups. Further, three comparison
examinations were employed to determine what groups scored significantly different than the
others. Individuals who reported having a deeper educational exposure to SLE scored
significantly higher on the LKQ than those who reported having only heard of SLE. This support
of the hypothesis indicates that just having heard of SLE holds no weight when it comes to being
knowledgeable about the disease mechanisms of SLE compared to having the opportunity to
learn about SLE in a learning environment. Additionally, those who reported having learned
about SLE in a deeper educational experience scored significantly higher on the LKQ than those
who reported no educational exposure.
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Although the finding may seem like common sense the novel analysis and examination of
these variables further substantiates the relationship between having educational exposure to
SLE and performing better on an SLE knowledge questionnaire. Finally, LKQ scores for
individuals who had heard of SLE did not differ significantly from those who reported no
educational exposure of SLE. These results indicate is that there seems to be no measurable
difference between SLE knowledge of someone who had only heard of SLE versus having no
exposure to SLE. These results are different than those from sample one.
The difference between results could be explained by the inability to exclude data from
sample one analyses because of not having the validity item. This hypothesis is why the validity
item was included in sample two and I propose that the questionnaire design better substantiates
sample two’s results. Additionally, the differences between the demographics of sample one and
sample two likely informed the motivation and effort of the participants’ performance on the
measures; thus, it is my second hypothesis regarding why the relationship between hearing of
SLE and having no educational exposure differed between the two samples.
The implications of having no measurable difference in SLE knowledge scores when
having only heard of the illness versus having no educational exposure to SLE is cause for some
alarm. The concern lies in the presumption that people who have heard of SLE are likely
unknowledgeable (according to these results) about the factual experiences of SLE but because
they have some awareness of the illness (i.e., the name) they could be contributing to the societal
misconceptions of SLE. If they are reinforcing false notions about SLE these individuals could
be perpetuating inaccurate facts as true. Increasing accurate knowledge has the possibility to
decrease the negative stigma and misconceptions of SLE that are associated with invisible
illnesses, like SLE.
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Results of Hypothesis 2
Hypothesis 2 was supported; individuals who report having close proximity to SLE
scored significantly higher on the LKQ than those who do not have disease proximity.
Rates of Disease Proximity. Participants who reported having SLE, often times also
reported having a family member with SLE. These results are indicative of the genetic nature of
SLE (Ramos & Brown, 2010; Sestak et al., 2007; Harley et al., 2006). Some participants even
reported knowing someone of every relation (self, immediate, extended and other), which due to
genetics and the likelihood of meeting other people with SLE through support groups these
results are not surprising.
Sample One. During the examination of hypothesis two of the draft version, results
indicated that there was a significant difference among the disease proximity groups. Additional
tests were employed to determine where the significant differences existed. Individuals in the
close proximity group were compared to those in the other proximity group and the scores
indicated no significant difference. The participants who reported having close proximity (self or
family) did not score differently than those who reported knowing someone else with SLE.
Initially, there is was a presumption that having someone of close relation (e.g., self, immediate
and extended family) would have more influence on the participant’s knowledge of SLE than
knowing someone of other relations. However, the findings indicated that it did not matter what
relation the person had to someone with SLE; rather, just knowing someone with SLE influenced
participants’ SLE knowledge. Someone reporting having an aunt with SLE may mean the same,
in terms of the influence of knowledge, for the participant as having a friend with SLE.
Those with close proximity to SLE scored significantly higher on the LKQ compared to
those with no proximity. Similarly, those who reported knowing someone else with SLE scored
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significantly better on the LKQ than those with no proximity. Therefore, these two results
indicated that having some personal relation to a person with SLE results in having significantly
better scores on the LKQ. As highlighted during the discussion of hypothesis one, although these
findings may seem like a simple assumption because no study has examined SLE knowledge and
the effects of disease proximity, this conclusion could not be confirmed. One possible
explanation for this could be that knowing someone with SLE provides the participant an
opportunity to learn about SLE through the personal experiences of someone diagnosed and/or
encourages the participant to educate him or herself on the disease. Of note, there was a
statistically significant association between those who identified as having proximity to SLE and
those who identified having educational exposure to SLE.
Sample Two. During the examination of hypothesis two for the revised version, the
overall analysis indicated that there was a significant difference among the proximity groups.
Post hoc tests were employed to determine where the significant differences existed. Although
the results from sample one should be taken with caution, the results of hypothesis two for the
second sample were identical. Participants who reported having a close proximity did not
statistically differ between those who reported knowing someone else with SLE. There seems to
be no indication that having a closer relationship (as categorized for this study) holds any
significance to resulting in higher knowledge. Those in the close proximity group and those in
the other proximity group scored significantly better on the LKQ than those who reported
knowing no one with SLE. Both results indicate that having some relation to a person with SLE
results in higher scores on the LKQ. It seems that when someone knows a person with SLE they
are more inclined or more likely to be exposed to facts or life experiences of SLE and therefore,
are more knowledge.
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One possible conclusion that could explain both samples’ findings, in terms of disease
proximity, is that having any relation to someone with SLE results in one being better educated
about the disease. It does not seem to differ between the relation that the person holds (close vs.
other) but having any proximity to SLE is associated with higher knowledge of SLE compared to
someone who knows no one with SLE. Ultimately, there are too many illnesses in our society to
be knowledgeable about all of them. Thus, knowing anyone with SLE might serve as an
incentive or an opportunity to discuss the disease. There is something important about knowing a
person with SLE that makes others more knowledgeable of the disease.
Study Limitations
Although the current studies’ hypotheses were supported, the samples utilized were not
the typical beginning point of questionnaire development, because they consisted of community
members and did not all have a direct relation to SLE. Sample one of the current study consisted
of young adults ranging from age 18 to 24 and sample two consisted of parents who ranged from
20 to 54 years old. A major consideration that has been mentioned is that the samples were not
ideal and furthermore, the findings from sample one should be taken with caution due to the
design flaw with no validity item. The ideal sample that previous researchers have utilized when
creating a novel or adapting a disease-specific questionnaire is one that incorporates
“knowledgeable participants”, this includes: patients, providers and those who work in a setting
where they need knowledge of the condition (Jaworski & Carey, 2007; Carey & Schroder, 2002;
Bergman et al., 2011; Wagner et al., 2005; White et al., 2006; Giordano et al., 2010; Winzenberg
et al., 2003; Edworthy, Devins, & Watson, 1995).
Provided that the samples utilized were not ideal, modifications had to occur when it
came to assigning participants to the groups. The participants were asked to report any
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educational exposure (heard of, read about, learned in class, attended lecture) and disease
proximity (self, immediate, extended family, other) regarding SLE. After responses were
tabulated, participants were categorized into only one group for each variable. Still, some
participants reported more than one degree of educational exposure or disease proximity.
Nevertheless, they were categorized into groups depending on which group they identified with
that had the lowest number of participants who also endorsed that item. For example, if someone
reported having attended a lecture on SLE and reported hearing about SLE, that person’s data
were put into the deeper educational group rather than the heard of SLE group. The same
occurred for disease proximity, if a participant endorsed having a self-diagnosis of SLE and
knowing someone else with SLE, their data was put into the close proximity group. Overall, this
grouping system was not ideal; however, since the results supported the hypotheses it may not be
as significant of a limitation.
A final limitation of the current study exists because the current study’s hypotheses;
however, altering the research aims could correct for the limitation. Individuals in both samples
were asked whether they had heard of SLE and in both samples some individuals reported not
having ever heard of it. For the purpose of the current hypotheses, these participants were
valuable. That was the case because I wanted to understand the relationship between all
dimensions of educational exposure and disease proximity, including those who identified as
having none. However, those participants’ data were still included in the item analyses of the
LKQ and the LKQ-R. The limitation lies in the issue that by keeping those individuals’ data in
the final analyses the interpretation of the knowledge questionnaire as a whole includes data
from individuals who had never even heard of SLE, which is not informative to understanding
what items are indicative of higher knowledge.
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Future Directions
Future research designs should be aimed to correct the limitations mentioned for the
current study. Further assessments of the LKQ-R should involve increasing the number of
participants within each educational exposure and disease proximity group. Although the
grouping procedure used provided appropriate participants, the number of participants in the
“none” groups (both for disease proximity and educational exposure) were substantially lower
than the number of participants in the other two groups in the two variables. Since some
participants endorsed more than one item (e.g., I have heard of SLE and I have read about it in a
class) there is a chance that a deeper understanding of SLE knowledge was lost because
participants’ data were not assessed based on more than one endorsement of each variable.
Future designs should employ independent groups to ensure that the results can be replicated.
For the current study, assumptions were made regarding which grouping category held
more weight; however, it is hard to presume the influence of various educational experiences or
the strength of the relationships participants reported on. Therefore, for future examinations
adding items to assess the perceived strength of the participants’ educational exposure to SLE
(i.e., to what degree did you learn about SLE in a class) as well as have a way to assess the
strength of the relationship between the participant and the person/people they identify as
knowing with SLE (i.e., does an immediate family member represent a stronger relationship vs.
extended family vs. knowing someone else) could provide more valuable information. A
participant only hearing of SLE on a television show versus having heard of SLE from a patient
could indicate a stronger relationship and expand the current understanding of the dimensions
that lead to higher knowledge rates (i.e., what is associated with more knowledge). Additionally,
a specifier aimed at determining the strength of the relationship that a person indicated when
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endorsing the disease proximity items could be informative. For example, a familial relationship
may not be conducive of more SLE knowledge; rather, having a close friend diagnosed may be a
stronger relationship that is conducive to a participant having more SLE knowledge.
This study was the first step in a broader research agenda designed to continue to
understand the influence of SLE knowledge. As the first step, the aim was to create a
questionnaire and conduct preliminary analyses to explore community members’ knowledge.
The next step should be to assess the utility of this measure in patient and provider samples.
Those are the samples that are theoretically presumed to have more knowledge of the disease and
thus, these samples would be the typical starting point (Reeve et al., 2013). Utilizing patients and
gathering psychometric data on the measure within this sample will allow for the future use of
the LKQ-R as an additional measure within protocols of patient education research. With further
use and examinations of the LKQ-R, it is the hope that it will become a common measure that
future researchers can use to assess the influence of SLE knowledge in various research designs.
Similarly, utilizing a provider sample will allow for the LKQ-R to be aimed at examining the
rates of knowledge that providers have of SLE and where gaps exist. New interventions can be
aimed to increase medical providers’ knowledge.
A final consideration is that the scope of the current study did not fully address all results
gathered. In fact, more data was gathered that could be examined to address alternate hypotheses,
including ones regarding what content areas of knowledge are scored at higher rates or which
various items on the LKQ-R are scores correctly more often than others. Understanding details
regarding which items are scored correctly more often could inform our considerations of what
knowledge themes are more well-known, which would be more novel insights. For instance,
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understanding what categories of disease proximity and educational exposure could have related
to a higher correct rate of individual items or the overall scale score.
Contribution to the Literature
Although some limitations exist, the findings from this study have provided a novel and
monumental method of exploring the dimension of SLE knowledge. As mentioned previously,
no measure like the LKQ-R exists; therefore, the creation of the LKQ-R is a novel contribution
to the field. The results from the assessment of the LKQ and the LKQ-R within the two
community samples provide the first examination of disease-specific knowledge and the effects
of education and proximity. The findings support the notion that educational experience and
disease proximity contribute to SLE knowledge, which are novel scientific contributions.
Clinical Implications
After continued testing within patient and provider samples, it is my hope that the LKQR will become a commonly utilized measurement tool to assess SLE knowledge in a systematic
way. The questionnaire could be used by providers to educate newly diagnosed patients. Patients
report being unsatisfied with the information that their providers give them after receiving a
diagnosis (Waldron et al., 2011). Therefore, having a tool like the LKQ-R could be used to
assess facts that are known and unknown among new patients. This tool could be used in the
medical settings to gather knowledge data at diagnosis and continue to gather follow-up
knowledge data. Additionally, this could help providers see what dimensions of SLE knowledge
(cause, timeline, etc.) patients are less knowledgeable of and provide them with additional
educational material on that specific domain. These findings extend the field by allowing
clinicians to be able to educate their patients on the reality SLE has on one’s health.
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For patients, the future use of the LKQ-R could be used within educational interventions.
Previous researchers have identified the success of behavioral changes that occur when a
component of disease-specific information is examined (Cunningham & Kashikar-Zuck, 2013;
Brown et al., 2012; Ramos-Remus et al., 2000). There had been no systematic way to assess the
knowledge of SLE, instead, authors created their own assessment variables to examine
knowledge (Konttinen et al.,1991; Young et al., 2002). The LKQ-R could become an essential
measurement tool for future SLE interventions research studies that want to assess disease
knowledge as a variable. Interventions that incorporate an educational aspect of disease have
shown significant improvements for patients’ mental and physical health experiences (Keefe,
1996; Keefe, Somers, & Martire, 2008; Evers et al., 2002; Rinaldi et al., 2006; Haupt et al.,
2005). Findings from these previous research studies provide support that with a tool like the
LKQ-R future interventions can become stronger by examining disease knowledge.
Conclusion
The first ever global assessment of SLE awareness was just released to the public in May
of 2016. The World Lupus Federation conducted a study across 16 countries with 16,911
participants to determine the public’s awareness and attitudes about SLE (Lupus Foundation of
America, 2016). The global assessment found that 36% of the participants did not know SLE
was a disease and 51% did not know that SLE results in severe health complications. The survey
also found that the misconception surrounding SLE are increasingly believed across the world.
Knowing that the global misconceptions of SLE are potentially worse than imagined assessing
accurate rates of knowledge and improving knowledge is a goal to correct the misconceptions.
The results of this study provided the foundational work that informs a research agenda
aimed at utilizing the LKQ as a novel assessment tool in SLE research. Through the four
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developmental phases, there was evidence that the LKQ-R is backed by medical information and
has the capabilities to identify levels of knowledge participants have of SLE based on their
education exposure and disease proximity. By creating the LKQ and LKQ-R the first
examination of community members’ knowledge of SLE was conducted. Furthermore, assessing
knowledge perceptions provided an additional novel finding related to whether participants have
actual knowledge or just perceive to have knowledge. Understanding what factors influence
community members’ knowledge is the first step in creating feasible and informative educational
interventions aimed to increase SLE awareness and decrease the false stigma associated with
SLE.
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Table 1. Frequency of demographic variables Draft LKQ
Variable
Gender

N

Valid Percentage

Female
Male

192
136

58
41.1

Single, never married
Married
Divorced

295
36
3

88.1
10.7
.9

White
African American
Asian
Latino/a
Mixed Race
Pacific Islander
Native American

278
13
4
17
18
1
4

83
3.9
1.2
5.1
5.4
.3
1.2

18
19
20
21
22
23
24

21
31
35
65
59
42
63

6.6
9.8
11.1
20.6
18.7
13.3
19.9

High School
Part-time College
Full-time College

14
21
165

4.2
6.3
49.1

Marital Status

Race/Ethnicity

Age

Current Student Enrollment

92

Table 2. Disease Proximity for Sample One
Have you been diagnosed with
lupus?
Yes
No
Prefer not to answer
Total

Frequency

Percent

3
328
8
336

0.9
96.7
2.4

Do you have an immediate family
member with lupus?
Yes
No
Prefer not to answer
Total

Frequency

Percent

8
319
9
336

2.4
94.9
2.7

Do you have an extended family
member with lupus?
Yes
No
Prefer not to answer
Total

Frequency

Percent

14
311
11
336

4.2
92.6
3.3

Do you know anyone else with
lupus?
Yes
No
Prefer not to answer
Total

Frequency

Percent

34
293
9
336

10.1
87.2
2.7

93

Valid
Percent
0.9
99.1

Valid
Percent
2.4
97.6

Valid
Percent
4.3
95.7

Valid
Percent
10.4
89.6

Table 3. Description of “Yes”
Immediate Family
Grandmother
In-Law
Sister
Mother
Parent
Omitted
Extended Family
Aunt
Cousin
First Cousin
Second Cousin
Other
Friend
Former (colleague, friend, roommate)
Neighbor
Friends’ parent
Acquaintance
Family friend
Friend of a friend
Colleague
Step dad
Hairdresser
Professor
Significant other of a family member
A celebrity
Program participant

Frequency
1
1
1
3
1
1
Frequency
7
3
1
3
Frequency
10
4
2
2
2
1
1
1
1
1
1
1
1
1

94

Table 4. Educational Exposure for Sample One
Have you heard of SLE?

Frequency

Percent

245
91
336

72.9
27.1

Frequency

Percent

65
270
335

19.3
80.4

Have you attended a lecture on
SLE?
Yes
No
Total

Frequency

Percent

6
329
336

1.8
97.9

Have you learned about SLE in a
class?
Yes
No
Total

Frequency

Percent

46
290
336

13.7
86.3

Yes
No
Total
Have you read about SLE?
Yes
No
Total

95

Valid
Percent
72.9
27.1

Valid
Percent
19.4
80.6

Valid
Percent
1.8
98.2

Valid
Percent
13.7
86.3

Table 5. Multiple Regression of Draft Items on Knowledge Scores
Item
Item 20: Swollen and painful joints are
symptoms of lupus.
Item 28: Lupus can lead to difficulties with
memory.
Item 23: Scientists believe that hormones,
genetics and the environment are all involved
in causing lupus.
Item 25: Patients are encouraged to minimize
stressful life events.
Item 9: African Americans are more likely to
be diagnosed over other racial groups.
Item 13: The degree of symptoms in people
with lupus is very similar.
Item 33: Certain medications can cause lupus
symptoms.
Item 7: Men are more likely to be diagnosed
with lupus than women.
Item 4: Women who have lupus and are
pregnant are considered to have a "high risk"
pregnancy.
Item 10: Lupus is a predictable disease.
Item 34: Lupus can be "caught" by sharing
personal items with someone who is
diagnosed
Item 32: People are born with a genetic
predisposition to getting lupus (more likely to
have it because of their genetic background).
Item 16: Being diagnosed with lupus places an
individual at greater risk for additional
medical diagnoses.

B
-.051

Std. Error
.007

Beta
-.197

t
-7.678

Sign.
.000

-.049

.008

-.146

-6.454

.000

-.052

.007

-.176

-7.765

.000

-.037

.006

-.147

-6.015

.000

-.035

.008

-.094

-4.514

.000

-.036

.009

-.096

-4.088

.000

-.039

.008

-.105

-4.705

.000

-.037

.009

-.086

-4.091

.000

-.021

.005

-.085

-4.146

.000

-.027
-.022

.010
.009

-.062
-.053

-2.815
-2.419

.005
.016

-.016

.007

-.051

-2.342

.020

.002

.001

.039

2.296

.022

96

Table 6. Item Difficulty, Item Correlation, Readability of Draft Version
Item

Item
Difficulty
With All (N)

Item 1: Fatigue
Item 2: Immune count test
Item 3: Heart disease
Item 4: High risk pregnancy
Item 5: Steroid medication
Item 6: Digestive issues
Item 7: Men diagnosed more
Item 8: Same virus
Item 9: AA disparity
Item 10: Predictable disease
Item 11: Single gene
Item 12: Skin rashes
Item 13: Symptom similarities
Item 14: Risk of more diagnoses
Item 15: Aging
Item 16: Multiple diagnoses
Item 17: Jaundice
Item 18: Great Imitator
Item 19: Symptoms begin soon
Item 20: Swollen/painful joints
Item 21: Negative impact on work
Item 22: Treatment can cure
Item 23: Hormone, gene, envt.
Item 24: Hair loss
Item 25: Minimize stressful events
Item 26: Specific cause know
Item 27: Distinguish b/w cells
Item 28: Memory difficulties
Item 29: Treatment stand/similar
Item 30: No exercising
Item 31: Kidney disease
Item 32: Genetic predisposition
Item 33: Meds cause symptoms
Item 34: “Catching” lupus
Item 35: Sensitivity to the sun
Item 36: Bipolar diagnosis
Item 37: Resolved skin rash
Item 38: Common for Caucasians
Overall

0.295 (336)
0.027 (335)
0.171 (332)
0.298 (336)
0.147 (334)
0.123 (334)
0.158 (336)
0.122 (335)
0.137 (336)
0.217 (336)
0.081 (335)
0.230 (335)
0.182 (336)
0.230 (335)
0.089 (336)
0.188 (335)
0.051 (334)
0.200 (335)
0.188 (335)
0.265 (336)
0.232 (336)
0.266 (335)
0.182 (336)
0.199 (336)
0.300 (336)
0.149 (335)
0.209 (335)
0.134 (336)
0.141 (334)
0.104 (336)
0.054 (334)
0.158 (336)
0.098 (336)
0.265 (336)
0.164 (335)
0.080 (336)
0.143 (335)
0.066 (335)
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Item
Difficulty
w/o DKs
(N)
0.733 (135)
0.145 (62)
0.877 (65)
0.944 (106)
0.817 (60)
0.732 (56)
0.768 (69)
0.804 (51)
0.596 (52)
0.859 (85)
0.614 (44)
0.917 (84)
0.693 (88)
0.917 (84)
0.476 (63)
0.940 (67)
0.283 (60)
0.944 (71)
0.887 (71)
0.927 (96)
0.788 (99)
0.937 (95)
0.871 (70)
0.763 (59)
0.971 (104)
0.820 (61)
0.921 (76)
0.804 (56)
0.758 (62)
0.761 (46)
0.419 (43)
0.855 (62)
0.611 (54)
0.881 (101)
0.859 (64)
0.563 (48)
0.828 (58)
0.458 (48)

Itemtotal
Corr.

Flesch
Reading
Ease

0.630
0.333
0.575
0.562
0.542
0.575
0.597
0.484
0.472
0.701
0.515
0.680
0.728
0.707
0.554
0.667
0.379
0.731
0.698
0.755
0.699
0.731
0.675
0.501
0.737
0.718
0.755
0.638
0.675
0.530
0.440
0.562
0.531
0.683
0.662
0.476
0.684
0.368
0.960

42.6
74.8
--67.5
29.5
47.5
72.6
95.9
32.5
32.5
69.7
73.8
57.2
17.3
34.5
42.6
64.9
37.4
42.6
71.8
47.8
75.8
41.5
90.9
40.0
49.5
44.9
42.6
64.9
17.9
61.3
42.7
31.5
50.4
52.8
10.5
60.7
26.6
49.3

FleschKincaid
Reading
Level
9.0
5.8
16.5
7.5
11.1
10.0
5.8
2.8
11.7
9.9
6.0
4.4
8.0
14.3
9.1
9.0
6.9
11.2
9.0
5.2
10.5
3.6
10.9
2.3
9.6
9.0
10.7
9.0
6.9
13.9
7.1
12.2
10.3
9.4
8.3
14.2
7.7
13.5
8.9

Table 7. Frequencies of LKQ-Draft Responses

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

19
20
21
22
23
24

Item

Correct
Response

Answered
Correctly

Answered
Don’t Know

99(29.5%)

Answered
Incorrectly
(w/o DKs)
36 (10.7%)

Fatigue is rarely experienced for lupus
patients.
The “immune count test” is the one used
for diagnosing lupus.
Lupus increases an individual’s risk of
premature cardiovascular disease (heart
disease)
Women who have lupus and are
pregnant are considered to have a “high
risk” pregnancy.
Steroid medication has the fewest
negative side effects.
Patients with lupus experience more
digestive issues, causing them to need to
use the restrooms more often.
Men are more likely to be diagnosed
with lupus than women.
Lupus us caused by the same virus that
is linked to HIV.
African Americans are more likely to be
diagnosed over other racial groups.
Lupus is a predictable disease.
Scientists believe there is a single gene
that causes lupus.
Skin rashes are symptoms of lupus.
The degrees of symptoms in people with
lupus are very similar.
Being diagnosed with lupus places an
individual at greater risk for additional
medical diagnoses.
Aging triggers lupus.
There are multiple types of lupus
diagnoses.
Yellowing of the skin (jaundice) is a
common symptom of lupus.
Lupus is often called “the great imitator”
because lupus mimics other health
conditions.
Lupus is diagnosed soon after symptoms
begin.
Swollen and painful joints are symptoms
of lupus.
A diagnosis of lupus does not have a
negative impact on a person’s ability to
work.
Treatment can cure lupus.
Scientists believe that hormones,
genetics, and the environment are all
involved in causing lupus.
Hair loss is a symptom of lupus.

False
False

9(2.7%)

53(15.8%)

273(81.3)

True

57(17.0%)

8(2.4%)

267 (79.5%)

True

100 (29.8%)

6(1.8%)

230(68.5)

False

49(14.6%)

11(3.3%)

274(81.5%)

True

41(12.2%)

15(4.5%)

278(82.7%)

False

53(15.8%)

16(4.8%)

267(79.5%)

10(3.0%)

284(84.5%)

False

41(12.2%)

201(59.8%)

True

31(9.2%)

21(6.3%)

284(84.5%)

False
False

73(21.7%)
27(8.0%)

12(3.6%)
17(5.1%)

251(74.7%)
291(86.6%)

True
False

77(22.9%)
61(18.2%)

7(2.1%)
27(8.0%)

251(74.7%)
248(73.8%)

True

77(22.9%)

7(2.1%)

251(74.7%)

False
True

30(8.9%)
63(18.8%)

33(9.8%)
4(1.2%)

273(81.3%)
267(79.5%)

False

17(5.1%)

43(12.8%)

274(81.5%)

True

67(19.9%)

4(1.2%)

264(78.6%)

False

63(18.8%)

8(2.4%)

264(78.6%)

True

89(26.5%)

7(2.1%)

240(71.4%)

False

78(23.2)

21(6.3%)

237(70.5%)

False
True

89(26.5%)
61(18.2%)

6(1.8%)
9(2.7%)

240(71.4%)
266(79.2%)

True

45(13.4%)

14(4.2%)

277(82.4%)
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25
26
27
28
29
30
31
32

33
34
35
36
37
38

Patients are encouraged to minimize
stressful life events.
The specific cause of lupus has been
identified by research scientist.
The immune system of someone with
lupus cannot distinguish between healthy
cells and harmful cells.
Lupus can lead to difficulties with
memory.
Treatment plans for lupus have been
standardized and are similar.
Patients are encouraged to not exercise
following diagnosis to help control
disease progression.
Kidney disease is one of the first
indicators of lupus.
People are born with a genetic
predisposition to getting lupus (more
likely to have it because of their genetic
background).
Certain medications can cause lupus
symptoms.
Lupus can be “caught” by sharing
personal items with someone who is
diagnosed.
Sensitivity to the sun is a concern for
lupus patients.
Bipolar disorder is the most common cooccurring mental health diagnosis.
Lupus skin rashes that occur can be
resolved easily with skin lotion.
Lupus is more common for Caucasians
than for individuals of Hispanic, Asian,
and Native American descent.

True

101(30.1%)

3(0.9%)

232(69.0%)

False

50(14.9%)

11(3.3%)

274(81.5%)

True

70(20.8%)

6(1.8%)

259(77.1%)

True

45(13.4%)

11(3.3%)

280(83.3%)

False

47(14.0%)

15(4.5%)

272(81.0%)

False

35(10.4%)

11(2.2%)

290(86.3%)

False

18(5.4%)

25(7.4%)

291(86.6%)

True

53(15.8%)

9(2.7%)

274(81.5%)

True

33(9.8%)

21(6.3%)

282(83.9%)

False

89(26.5%)

12(3.6%)

235(69.9%)

True

55(16.4%)

9(2.7%)

271(80.7%)

False

27(8.0%)

21(6.3%)

288(85.7%)

False

48(14.3%)

10(3.0%)

277(82.4%)

False

22(6.5%)

26(7.7%)

287(85.4%)
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Table 8. Frequency of Sample Two demographic variables
Variable
Gender

N

Valid Percentage

Female
Male

144
41

77.8
22.2

Married
Single, never married
Divorced

137
32
16

73.3
17.1
8.6

White
African American
Asian
Latino/a
Mixed Race
Middle Eastern
Native American

154
10
3
8
7
1
2

83.2
5.4
1.6
4.3
3.8
0.5
1.1

20-24
25-29
30-34
35-39
40-44
45-49
50-54

13
37
67
41
17
5
3

7.1
21.0
36.7
22.4
9.2
2.6
1.6

12 (HS graduate)
13
14 (Associate Degree)
15
16 (Bachelor Degree)
17
18(Master Degree)
19
20 (Doctorate/Professional Degree)

16
25
23
12
63
4
24
5
14

8.6
13.4
12.4
6.5
33.9
2.2
12.9
2.7
7.5

Marital Status

Race/Ethnicity

Age

Years of Education
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Table 9. Disease Proximity for Sample Two
Have you been diagnosed with
lupus?
Yes
No
Total

Frequency

Percent

3
182
186

1.6
97.3

Do you have an immediate family
member with lupus?
Yes
No
Total

Frequency

Percent

4
182
186

2.1
96.8

Do you have an extended family
member with lupus?
Yes
No
Total

Frequency

Percent

18
168
186

9.6
89.4

Do you know anyone else with
lupus?
Yes
No
Total

Frequency

Percent

48
138
186

25.5
73.4
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Valid
Percent
1.6
98.4

Valid
Percent
2.2
97.8

Valid
Percent
9.7
90.3

Valid
Percent
25.8
74.2

Table 10. Description of “Yes”
Immediate Family

Frequency
2
2
Frequency
2
6
1
1
1
1
2
1
1
1
Frequency
24
2
2
1
4
3
2
1

Mother
Omitted
Extended Family
Aunt
Cousin
Aunts and Cousins*
Great Aunt
Husband’s Uncle
Husband’s Cousin
Paternal Aunt
Paternal Great-Grandmother
Through Marriage
Step Father-in-law
Other
Friend
Former (colleague/friend)
Childhood/high school Friend
Friends’ grandparent
Acquaintance
Family friend
Co-worker/Colleague
Friend, coworker, underwent testing
myself**
Child’s former teacher
Neighbor
Job Patient

1
1
1

*Cannot infer further, remains as an answer of 1
** Cannot infer further, remains an answer of 1
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Table 11. Educational Exposure for Sample Two
Have you heard of SLE?

Frequency

Percent

179
9
188

27.1

Frequency

Percent

84
104
188

44.7
55.3

Have you attended a lecture on
SLE?
Yes
No
Total

Frequency

Percent

6
181
187

3.2
96.3

Have you learned about SLE in a
class?
Yes
No
Total

Frequency

Percent

24
163
187

12.8
86.7

Yes
No
Total
Have you read about SLE?
Yes
No
Total
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Valid
Percent
72.9
27.1

Valid
Percent
44.7
55.3

Valid
Percent
3.2
98.8

Valid
Percent
12.8
87.2

Table 12. Item Difficulty, Item Discrimination, Item Correlation, Readability of Revised Version
Item

Item 1: Swollen/painful joints
Item 2: Memory Difficulties
Item 3: Horm, Envir, Gene
Item 4: Minimize stress
Item 5: AA disparity
Item 6: Symptoms Similar
Item 7:Distingusih Cells
Item 8: Medications cause
Item 9: Men diagnosed more
Item 10: High risk pregnancy
Item 11: Predictable
Item 12: Spread by sharing
Item 13: Genetic predisposition
Item 14: Risk of more diagnoses
Item 15: Premature heart disease
Item 16: Fatigue
Item 17: Severity is similar
Item 18: Great Imitator
Item 19: Hair loss/thinning
Item 20: Validity Item
Item 21: Skin rash
Item 22: Sensitivity to sun
Item 23: Immune count test
Item 24: Years to diagnose
Item 25: Immune system weak
Item 26: Diagnose soon
Item 27: Bipolar most common
Item 28: Caucasians more
Item 29: Take years to diagnose
Item 30: Aging triggers
Item 31: Kidney disease
Item 32: Jaundice symptom
Item 33: Multiple diagnoses
Item 34: Treatment can cure
Overall

Item
Difficulty
With All
(N)
0.643(188)
0.316(187)
0.380(187)
0.586(186)
0.342(187)
0.388(188)
0.583(187)
0.255(188)
0.319(188)
0.473(188)
0.535(185)
0.706(187)
0.404(188)
0.535(187)
0.251(187)
0.606(188)
0.489(188)
0.468(188)
0.439(187)
1.00 (188)
0.428(187)
0.441(188)
0.048(188)
0.484(188)
0.711(187)
0.380(187)
0.128(188)
0.188(186)
0.495(188)
0.085(188)
0.085(188)
0.107(187)
0.351(188)
0.510 (188)

--indicates the item was not analyzed
** item exceeded the score range
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Item
Discrim.

Itemtotal
Corr.

Flesch
Reading
Ease

74.6
62.7
70.6
74.4
46.2
62.7
84.1
51.0
70.6
68.6
75.9
52.2
45.1
85.1
54.9
58.9
66.7
78.4
84.2
--64.3
70.6
11.7
66.7
66.6
58.7
29.4
43.1
74.5
13.7
18.7
20.1
60.8
70.6

0.626
0.476
0.589
0.662
0.400
0.560
0.707
0.447
0.563
0.575
0.622
0.609
0.446
0.743
0.477
0.605
0.608
0.658
0.616
--0.560
0.595
0.246
0.593
0.710
0.557
0.361
0.403
0.671
0.185
0.272
0.256
0.523
0.593
0.940

71.8
42.6
46.6
40.0
32.5
57.2
44.9
31.5
72.6
67.5
32.5
50.4
45.0
17.3
**
42.6
29.5
37.4
82.3
--73.8
52.8
74.8
66.1
66.1
42.6
17.9
26.6
66.1
34.5
61.3
64.9
42.6
75.8
49.6

FleschKincaid
Reading
Level
5.2
9.0
9.7
9.6
11.7
8.0
10.7
10.3
5.8
7.5
9.9
9.4
11.6
12.0
12.0
9.0
11.1
11.2
3.7
--4.4
8.3
5.8
6.2
6.2
9.0
12.0
12.0
6.2
9.1
7.1
6.9
9.0
3.6
8.7

Table 13. Frequencies of LKQ-Revised Responses

1
2
3
4
5
6
7
8
9
10
11
12
13

14
15
16
17
18
19
20
21
22
23
24

Item

Correct
Response

Answered
Correctly

Swollen and painful joints are symptoms of
lupus.
Lupus can lead to difficulties with memory.
The onset of lupus is triggered by
hormones, genetics and the environment.
Patients are encouraged to minimize
stressful life events.
African Americans are more likely to be
diagnosed over other racial groups.
The degree of symptoms in people with
lupus is very similar.
The immune system, of someone with
lupus, cannot distinguish between healthy
cells and harmful cells.
Certain medications can cause lupus
symptoms.
Men are more likely to be diagnosed with
lupus than women.
Women who have lupus and are pregnant
are considered to have a high risk
pregnancy.
Lupus is a predictable disease.
Lupus can be spread by sharing personal
items with someone who is diagnosed.
People are born with a genetic
predisposition for lupus (more likely to
have it because of their genetic
background).
Being diagnosed with lupus places an
individual at greater risk for additional
medical diagnoses.
Lupus increases an individuals’ risk of
premature cardiovascular disease (heart
disease).
Fatigue is rarely experienced for lupus
patients.
The severity of symptoms is similar across
patients.
Lupus is often called the great imitator
because lupus mimics other health
conditions.
Hair loss/thinning is a symptom of lupus.

True

Please answer true for this item.
Skin rashes are symptoms of lupus.
Sensitivity to the sun is a concern for lupus
patients.
The immune count test is the one test used
for diagnosing lupus.
It may take many years to confirm a
diagnosis.

Answered
Don’t Know

121(64.4%)

Answered
Incorrectly
(w/o DKs)
2(1.1%)

True
True

59(31.6%)
71(38.0%)

12(6.4%)
9(4.8%)

116(62.0%)
107 (56.2%)

True

109(58.6%)

4(2.2%)

73(39.2%)

True

64(34.2%)

15(8.0%)

108(57.8%)

False

73(38.8%)

29(15.4%)

86(45.7%)

True

109(58.3%)

2(1.1%)

76(40.6%)

True

48(25.5%)

19(10.1%)

121(64.4%)

65(34.6%)

False

60(31.9%)

9(4.8%)

119(63.3%)

True

89(47.3%)

6(3.2%)

93(49.5%)

False
False

99(53.5%)
132(70.6%)

9(4.9%)
9(4.8%)

77(41.6%)
46(24.6%)

True

76(40.4%)

8(4.3%)

104(55.3%)

True

100(53.5%)

1(0.5%)

86(46.0%)

True

47(25.1%)

6(3.2%)

134(71.7%)

False

114(60.6%)

25(13.3%)

49(26.1%)

False

92(48.9%)

20(10.6%)

76(40.4%)

True

88(46.8%)

4(2.1%)

96(51.1%)

True

82(43.9%)

6(3.2%)

99(52.9%)

True
True
True

188(100%)
80(42.8%)
83(44.1%)

--5(2.7%)
5(2.7%)

--102(54.5%)
100(53.2%)

False

9(4.8%)

45(23.9%)

134(71.3%)

True

91(48.4%)

7(3.7%)

90(47.9%)
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25
26
27
28
29
30
31
32
33
34

The immune system of patients with lupus
is weakened.
Lupus is diagnosed soon after symptoms
begin.
Bi-polar disorder is the most common cooccurring mental health diagnosis for lupus
patients.
Lupus is more common for Caucasians than
for individuals of Hispanic, Asian, and
Native American decent.
It may take many years to confirm a
diagnosis.
Aging triggers lupus.
Kidney disease is one of the first indicators
of lupus.
Yellowing of the skin (jaundice) is a
common symptom of lupus.
There are multiple types of lupus diagnoses.
Treatment can cure lupus.

True

133(71.1%)

5(2.7%)

49(26.2%)

False

71(38.0%)

18(9.6%)

98(52.4%)

False

24(12.8%)

19(10.1%)

145(77.1%)

False

35(18.8%)

20(10.8%)

131(70.4%)

True

93(49.5%)

5(2.7%)

90(47.9%)

False
False

16(8.5%)
16(8.5%)

23(12.2%)
23(12.2%)

149(79.3%)
149(79.3%)

False

20(10.7%)

30(16.0%)

137(73.3%)

True
False

66(35.1%)
96(51.1%)

11(5.9%)
7(3.7%)

111(59.0%)
85(45.2%)
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APPENDIX A:
Medical provider Interview Protocol
A.

B.

C.

Introduction
1. Thanks for coming- brief explanation of the protocol. This should take no longer
than 60 minutes. Describe importance of information they are providing-You are
part of a critical phase of developing the first ever lupus knowledge questionnaire
to assess both patients’ disease knowledge and knowledge of SLE among the
general public.
2. Explain and read (provide) Informed Consent and then they will be asked to
complete a demographic survey on my laptop through Qualtrics.
Purpose
1. I want the questionnaire to be physician and patient driven which is why I want to
hear about your experiences with living with lupus.
2. I want to know about your ideas, suggestions and comments about what questions
and content should be included in an SLE knowledge questionnaire. As you are a
medical professional who has had experience providing patients with information
related to lupus you know what questions are asked or what should be asked. I
want to use that and your medical background to understand how I can create a
useful questionnaire.
Procedure
1. Session will be recorded- This is all confidential, your name will not be collected with your
responses. Anything you say here is only used for the purpose of my research and the LKQ.

Begin – turn on recorder
For the first set of questions, I’m going to ask you about your experiences with patients and your
thoughts on the type of knowledge they want to gain, the type of knowledge you think they should
have, and any misconceptions they have about SLE. For the second set of questions, I’m going to
ask you about the resources you provide to patients. And finally, for the third set of questions,
I’m going to ask you about knowledge you think would be useful for family members or those
caring for people with SLE to have, as well as people within the general public.
1. Tell me a little bit about your medical background and the types of conditions you see in
patients?
SET 1: Thoughts on the type of knowledge you think patients should have
2. What information do you think is important for patients to know?
a) What are some specific questions related to the cause of SLE that would be
beneficial to assess in a knowledge questionnaire? (E.g. SLE is caused by
smoking – T/F)
b) What are some specific questions related to the symptoms that occur in SLE that
would be beneficial to assess? (E.g. Groups of symptoms of SLE are often times
described as flares- T/F)
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c) What are some specific questions related to the course of SLE that would be
beneficial to assess? (E.g. The average length of time it takes to receive a
diagnosis is 5 years –T/F)
d) What are some specific questions related to the controllability of SLE that would
be beneficial to assess? (E.g. Medication use? Exercise? Eating habits?)
e) What are some specific questions related to the chronic style of SLE that would
be beneficial to assess? (E.g. Longevity? Quality of life?)
3. What misconceptions do patients tend to have about their diagnosis?
4. What questions regarding SLE do patients not ask about that they should?
SET 2: The resources used to educate patients
1. How do you educate patients about SLE?

a) Prompt: Could you explain what you say to someone who is diagnosed and walk
me through your explanation of the disease?
2. What resources do you provide them?
a) Prompt: Pamphlets, handouts (from where) or reliable internet sources (from where)

1. What has been your experience with this?
2. How well does this or does this not work?
3. What resources do you have at your disposal to assist you in providing
education/knowledge to your SLE patients? (If not already answered from the above
question)
4. What other resources (if any) would be helpful to have at your disposal when trying to educate
patients?
5. Are there any resources that you find counter-productive? For instance, are there are websites that
give patients an unrealistic view of the disease?

SET 3: Useful for family members/caregivers/general public to have
1. What should people know about SLE to have a good general understanding of the illness and how
it is experienced by people? (i.e. causes, symptoms, treatment, etc.) (Not patients)
2. What information do you think is important for family members or caretakers of patients to
know?
3. What misconceptions do you think the general public tends to have about the diagnosis?
4. Any other thoughts, comments or suggestions before we conclude the interview.

THANK YOU! After I compile all of the information from these interviews I will create a draft
of the LKQ. Once the draft has been created I would like to contact you and get some feedback
on the questions before I begin testing it within patient and community samples. Would you be
okay with this?

108

APPENDIX B:
Materials for Medical Provider Verification
Here you will be asked to read over the lupus knowledge questionnaire draft and provide a
relevance score for each item (1= not relevant/exclude to 4= highly relevant/keep as is). After
providing a 1-4 score for each item then you will be asked to provide feedback on clarity and
accuracy. This will give you the opportunity to provide edits or comments related to that item.
Relevance: Is the item relevant to be involved in a general SLE-specific disease knowledge?
Clarity: Is the item clear in regard to the wording?
Accuracy: Does the item contain accurate medical information?
If you indicate a 2 or a 3 please provide recommendations or alterations that could be
added to make the question be rated a 4.
*****
This questionnaire will be given to a community sample of individuals for initial testing.
Therefore, it is meant to be a more generalist questionnaire rather than specific details for
patients or providers.
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1

Item on the lupus knowledge questionnaire (LKQ)
Hair loss is a symptom of lupus –ANS: T

Relevance

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.

2

Skin rashes are symptoms of lupus–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
3

Sensitivity to the sun is a concern for lupus patients–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
4

Swollen and painful joints are symptoms of lupus–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
5

Yellowing of the skin (jaundice) is a common symptom of
lupus–ANS: F
Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
6

Kidney disease is one of the first indicators of lupus–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
7

The degree of symptoms in people with lupus are very similar–
ANS: F
Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
8

Fatigue is rarely experienced for lupus patients–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
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9

Lupus is often called “the great imitator” because lupus mimics
other health conditions–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
10

Lupus is diagnosed soon after symptoms begin–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
11

The “immune count test” is the one test used for diagnosing
lupus–ANS: F
Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
12

The immune system, of someone with lupus, cannot distinguish
between healthy cells and harmful cells–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
13

Men are more likely to be diagnosed with lupus than women–
ANS: F
Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
14

Lupus is caused by the same virus that is linked to HIV–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
15

Scientists believe there is a single gene that causes lupus–ANS:
F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
16

African Americans are more likely to be diagnosed over other
racial groups–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
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17

The specific cause of lupus has been identified by research
scientists–ANS: F
Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
18

People are born with a genetic predisposition to getting lupus
(more likely to have it because of their genetic background) –
ANS: T
Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
19

Scientists believe that hormones, genetics, and the environment
are all involved in causing lupus–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
20

Aging triggers lupus–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
21

There are multiple types of lupus diagnoses–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
22

Certain medications can cause lupus symptoms –ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
23

Lupus can be “caught” by sharing personal items with someone
who is diagnosed–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
24

Lupus is more common for Caucasians than for individuals of
Hispanic, Asian, and Native American decent–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
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25

Treatment can cure lupus–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
26

Treatment plans for lupus have been standardized and are all
similar–ANS: F
Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
27

Steroid medication has the fewest negative side effects–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
28

Lupus is a predictable disease–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
29

Patients are encouraged to not exercise following diagnosis to
help control disease progression–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
30

Being diagnosed with lupus places an individual at greater risk
for additional medical diagnoses–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
31

Patients are encouraged to minimize stressful life events–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
32

Bi-polar disorder is the most common co-occurring mental
health diagnosis–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
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33

Women who have lupus and are pregnant are considered to have
a “high risk” pregnancy–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
34

Lupus skin rashes that occur can be resolved easily with skin
lotion–ANS: F
Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
35

Lupus can lead to difficulties with memory–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.

36

Patients with lupus experience more digestive issues, causing
them to need restrooms more often–ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.

37

A diagnosis of lupus does not have a negative impact on a
person’s ability to work–ANS: F

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.

38

Lupus increases an individual’s risk of premature cardiovascular
disease (heart disease) –ANS: T

Do you have any changes that you would like to see applied in terms of accuracy or clarification of
the item? Add any comments or edits below.
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APPENDIX C:
Demographic and Educational Exposure/ Disease Proximity Questions
Instructions: Fill out all demographic items below as honestly as possible. Please fill in boxes or
type responses when necessary. Please read all of the directions before continuing though the
survey.
1) What gender do you identify with?
• Female
• Male
• Other (please specify) ____________________
2) With which race and/or ethnicity do you identify (select all that apply)
• Asian
• Pacific Islander
• Black/African American
• Hispanic/Latino/a
• Native American
• White/Caucasian
• Mixed
3) What is your current age? _____
4) Are you currently a student?
• Yes, high school
• Yes, part-time college
• Yes, full-time college
• No
5) What is your marital status?
• Single (never married)
• Married
• Separated
• Divorced
6) How many years of education do you have? ______
(Educational exposure Items)
1. Have you heard of SLE?
2. Have you read about SLE?
3. Have you attended a lecture about SLE?
4. Have you learned able SLE in a class?
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Yes
m
m
m
m

No
m
m
m
m

How confident are you in the accuracy of your current knowledge about SLE?
Not
Somewhat
N/A or
Confident
Extremely
Confident
Confident
Unsure
Confident
Confidence
Lupus
m
m
m
m
m
(Disease Proximity Items)
You may choose to leave these items blank if you are not comfortable disclosing. Please
consider responding if you are comfortable. Your responses are confidential.
a)
b)
c)
d)

Have you been diagnosed with Lupus? ____ Yes _____No
Do you have an immediate family member diagnosed with Lupus? ___Yes ___ No
Has anyone in your extended family ever been diagnosed with Lupus? __Yes ___No
Do you know anyone else who has been diagnosed with Lupus? ___ Yes ____ No
*** LKQ will appear here***

Following completion of the questionnaire participants will be asked to complete these final two items.

How well do you believe you did on the task above? (0= I did not get any items correct, 100= I
got all the items correct.)
0%_______________100%
Based on your knowledge of lupus how do you believe you compare to the average person?
m I have more knowledge than the average person
m I have some more knowledge than the average person
m I am the same as the average person
m I have less knowledge than the average person
m I know nothing compared to the average person
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APPENDIX D:
CVI Verification Feedback from Providers
Original
1a
2a
3a

4 ab

5c

6a

7 ab

Hair loss is a
symptom of
lupus
Skin rashes are
symptoms of
lupus
Sensitivity to
the sun is a
concern for
lupus patients
Swollen and
painful joints
are symptoms
of lupus
Yellowing of
the skin
(jaundice) is a
common
symptom of
lupus
Kidney disease
is one of the
first indicators
of lupus
The degree of
symptoms in
people with
lupus are very
similar

P1
score
4
4

P1 edits

P2
score
4

hair loss or
thinning hair
Butterfly rash
across bridge of
nose and cheeks.

3

4

Patients usually
complain of joint
stiffness and pain
that does not
resolve after
activity.

P2 edits

P3
score
3

P3 edits

Agree
Rate
100%

4

3

100%

4

4

100%

4

2

67%

1

4

Generally not
true unless has
hepatitis with
the disease
false

1

33%

1

4

I cannot agreefalse

3

67%

4

not true- false

1

67%

4

false

4

100%

3

100%

2 /4**

8a

Fatigue is rarely
experienced for
lupus patients

4

9a

Lupus is often
called “the great
imitator”
because lupus
mimics other

4

People are
individually
affected by this
disease in
different ways.
Some people
have more severe
symptoms while
others have less
severe
symptoms.
One of the first
complaints of
patient
presenting with
lupus signs is
generalized
fatigue.

3
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10 a

11 a

12 a

13 b

14 d

15 d

16 ab

17 d

health
conditions
Lupus is
diagnosed soon
after symptoms
begin

1/4 **

The “immune
count test” is
the one test
used for
diagnosing
lupus
The immune
system, of
someone with
lupus, cannot
distinguish
between healthy
cells and
harmful cells
Men are more
likely to be
diagnosed with
lupus than
women
Lupus is caused
by the same
virus that is
linked to HIV
Scientists
believe there is
a single gene
that causes
lupus
African
Americans are
more likely to
be diagnosed
over other racial
groups

1

The specific
cause of lupus
has been
identified by
research
scientists

4

It may take many
years for the
affirmative of the
diagnosis.

Patients with
lupus usually
have a weakened
immune system
than others.

4

false

1

67%

4

false

3

67%

4

not true- it is
the
autoantibodies

2

67%

1

4

1

33%

1

2

1

0%

1

2

1

0%

4

4

3

100%

1

4

1

33%
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I would have
thought
otherwiseIncidence
maybe higherbut due to
economic
factors and
access to
decent carethey are less
likely to be
diagnosed
earlier.

18 ab

19 ab

20 c
21 ab

22 ab

23 b

24 c

25 a

People are born
with a genetic
predisposition
to getting lupus
(more likely to
have it because
of their genetic
background)
Scientists
believe that
hormones,
genetics, and
the environment
are all involved
in causing lupus
Aging triggers
lupus
There are
multiple types
of lupus
diagnoses
Certain
medications can
cause lupus
symptoms
Lupus can be
“caught” by
sharing
personal items
with someone
who is
diagnosed
Lupus is more
common for
Caucasians than
for individuals
of Hispanic,
Asian, and
Native
American
decent
Treatment can
cure lupus

4

4

2

67%

3

3

3

100%

1

3

1

33%

4

4

2

67%

4

4

3

100%

1

4

1

33%

2

4

1

33%

Hormones?
Environment?
-causing?modulating
maybe not
cause

1/4 **

This cannot be
treated, but
symptoms may
be managed.

4

2

67%

All patients have
different
manifestations of
lupus, therefore
treatment would
be different.

4

1

67%

4

1

33%

26 d

Treatment plans
for lupus have
been
standardized
and are all
similar

1/4 **

27 d

Steroid
medication has

2
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28 b
29 d

30 a

31 b

32 c

33 ab

34 d

35 ab
36 d

the fewest
negative side
effects
Lupus is a
predictable
disease
Patients are
encouraged to
not exercise
following
diagnosis to
help control
disease
progression
Being
diagnosed with
lupus places an
individual at
greater risk for
additional
medical
diagnoses
Patients are
encouraged to
minimize
stressful life
events
Bi-polar
disorder is the
most common
co-occurring
mental health
diagnosis
Women who
have lupus and
are pregnant are
considered to
have a “high
risk” pregnancy
Lupus skin
rashes that
occur can be
resolved easily
with skin lotion
Lupus can lead
to difficulties
with memory
Patients with
lupus
experience
more digestive
issues, causing
them to need
restrooms more
often

1

4

1

33%

1/4 **

All patients have
different
manifestations of
lupus, therefore
treatment would
be different.

4

1

67%

4

Lupus may affect
multiple organs,
which then may
causes other
diseases.

4

1

67%

4

stress may
decrease immune
system, and also
flare symptoms

4

3

100%

1

4

1

33%

4

4

3

67%

1

4

1

33%

4

4

3

67%

4

3

2

67%
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37 d

38 a

A diagnosis of
lupus does not
have a negative
impact on a
person’s ability
to work
Lupus increases
an individual’s
risk of
premature
cardiovascular
disease (heart
disease)

1/4 **

this is a life
changing
diagnosis

4

4

3

100%

4

4

100%

a = items retained for the revised version based on CVI
b = items retained for the revised version based on regression
c = items retained for the revised version based on item difficulty/subjective
d = items excluded from revised version
(Of note, the items may or may not have gone through wording edits based off feedback between the draft version and the revised version)
** = indicates items as their original score/score change after edits were accounted for
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APPENDIX E:
LKQ Items in CSM Dimensions
Identity
Jaundice is a common symptom
Kidney disease is the first disease indicator
Swollen/painful joint are common symptoms
Skin rashes are symptoms
Sun sensitivity is a concern
Hair loss is a symptom
Fatigue is not experienced

P1
1
1
4
4
3
4
4

P2
4
4
4
4
4
4
4

P3
1
3
2
3
4
3
4

CVI
33%
67%
67%
100%
100%
100%
100%

Cause
Single gene causes lupus
Aging triggers lupus
Specific cause is known
Men diagnosed more
Same virus as HIV
Caucasian are diagnosed more than other ethnicities.
Immune system cannot distinguish cells
Genetic predisposition for lupus
African Americans more often diagnosed
Medications cause symptoms
Hormone, genes, environment all play a role

P1
1
1
1
1
1
2
4
4
4
4
3

P2
2
3
4
4
4
4
4
4
4
4
3

P3
1
1
1
1
1
1
2
2
3
3
3

CVI
0%
33%
33%
33%
33%
33%
67%
67%
100%
100%
100%

Time-line
Can be caught by sharing items.
Lupus is diagnosed soon
“Immune count test” is the one test used.

P1
1
1- Edits
1

P2
4
4
4

P3
1
3
3

CVI
33%
67% / 100%
67%

Controllability/Curability
Lupus is a predictable disease
Patients are encouraged to not exercise
Steroid medications cause least side effects.
Treatment can cure lupus.
Treatments are standard/similar.
Symptom Severity is the same for patients
Additional diagnoses are common after lupus.
Patients are encouraged to minimize stress.

P1
1
1
2
1- Edits
1- Edits
2- Edits
4
4

P2
4
4
4
4
4
4
4
4

P3
1
1
1
2
1
1
1
3

CVI
33%
33%
33%
33% / 67%
33% / 67%
33% / 67%
67%
100%

Consequence
Bi-polar is the most common co-morbid mental health.
Skin lotion can eliminate rash symptoms
There are multiple types of lupus diagnoses.
Digestive issues are increased
Patients have negative work abilities
Lupus is also known as the Great Imitator.
Patients have memory concerns
Mothers with lupus will have a high risk pregnancy
Premature heart disease is a risk

P1
1
1
4
4
1- Edits
4
4
4
4

P2
4
4
4
3
4
3
4
4
4

P3
1
1
2
2
3
3
3
3
4

CVI
33%
33%
67%
67%
67% / 100%
100%
100%
100%
100%
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APPENDIX F:
Draft LKQ Version
Instructions: Please complete the following questionnaire that contains 38 items that will ask you about your
general knowledge about systemic lupus erythematosus, more commonly referred to as lupus. The items are all
designed as True/False or Don’t Know. Please answer the following items based on your current level of knowledge
about lupus and be as honest as you can.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Item
Fatigue is rarely experienced for lupus patients
The “immune count test” is the one test used for diagnosing lupus
Lupus increases an individual’s risk of premature cardiovascular disease (heart
disease)
Women who have lupus and are pregnant are considered to have a “high risk”
pregnancy
Steroid medication has the fewest negative side effects
Patients with lupus experience more digestive issues, causing them to need to
use restrooms more
Men are more likely to be diagnosed with lupus than women
Lupus is caused by the same virus that is linked to HIV
African Americans are more likely to be diagnosed over other racial groups
Lupus is a predictable disease
Scientists believe there is a single gene that causes lupus
Skin rashes are symptoms of lupus
The degree of symptoms in people with lupus are very similar
Being diagnosed with lupus places an individual at greater risk for additional
medical diagnoses
Aging triggers lupus
There are multiple types of lupus diagnoses
Yellowing of the skin (jaundice) is a common symptom of lupus
Lupus is often called “the great imitator” because lupus mimics other health
conditions
Lupus is diagnosed soon after symptoms begin
Swollen and painful joints are symptoms of lupus
A diagnosis of lupus does not have a negative impact on a person’s ability to
work
Treatment can cure lupus
Scientists believe that hormones, genetics, and the environment are all involved
in causing lupus
Hair loss is a symptom of lupus
Patients are encouraged to minimize stressful life events
The specific cause of lupus has been identified by research scientists
The immune system, of someone with lupus, cannot distinguish between healthy
cells and harmful cells
Lupus can lead to difficulties with memory
Treatment plans for lupus have been standardized and are similar
Patients are encouraged to not exercise following diagnosis to help control
disease progression
Kidney disease is one of the first indicators of lupus
People are born with a genetic predisposition to getting lupus (more likely to
have it because of their genetic background)
Certain medications can cause lupus symptoms
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True

False
False
False

True
True
False
True
False
False
True
False
False
True
False
True
False
True
False
True
False
True
False
False
True
True
True
False
True
True
False
False
False
True
True

DK

34
35
36
37
38

Lupus can be “caught” by sharing personal items with someone who is
diagnosed
Sensitivity to the sun is a concern for lupus patients
Bi-polar disorder is the most common co-occurring mental health diagnosis
Lupus skin rashes that occur can be resolved easily with skin lotion
Lupus is more common for Caucasians than for individuals of Hispanic, Asian,
and Native American decent
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False
True
False
False
False

APPENDIX G:
Revised LKQ Version
Instructions: Please complete the following questionnaire that contains 34 items that will ask you about your
general knowledge about systemic lupus erythematosus, more commonly referred to as lupus. The items are all
designed as True/False or Don’t Know. Please answer the following items based on your current level of knowledge
about lupus and be as honest as you can.
Item
Swollen and painful joints are symptoms of lupus.
Lupus can lead to difficulties with memory.
The onset of lupus is triggered by hormones, genetics and the environment.

True
True
True
True
True
True

29
30
31
32
33

Patients are encouraged to minimize stressful life events.
African Americans are more likely to be diagnosed over other racial groups.
The degree of symptoms in people with lupus is very similar.
The immune system, of someone with lupus, cannot distinguish between healthy
cells and harmful cells.
Certain medications can cause lupus symptoms.
Men are more likely to be diagnosed with lupus than women.
Women who have lupus and are pregnant are considered to have a high risk
pregnancy.
Lupus is a predictable disease.
Lupus can be spread by sharing personal items with someone who is diagnosed.
People are born with a genetic predisposition for lupus (more likely to have it
because of their genetic background).
Being diagnosed with lupus places an individual at greater risk for additional
medical diagnoses.
Lupus increases an individuals’ risk of premature cardiovascular disease (heart
disease).
Fatigue is rarely experienced for lupus patients.
The severity of symptoms is similar across patients.
Lupus is often called the great imitator because lupus mimics other health
conditions.
Hair loss/thinning is a symptom of lupus.
Please answer true for this item.
Skin rashes are symptoms of lupus.
Sensitivity to the sun is a concern for lupus patients.
The immune count test is the one test used for diagnosing lupus.
It may take many years to confirm a diagnosis.
The immune system of patients with lupus is weakened.
Lupus is diagnosed soon after symptoms begin.
Bi-polar disorder is the most common co-occurring mental health diagnosis for
lupus patients.
Lupus is more common for Caucasians than for individuals of Hispanic, Asian,
and Native American decent.
It may take many years to confirm a diagnosis.
Aging triggers lupus.
Kidney disease is one of the first indicators of lupus.
Yellowing of the skin (jaundice) is a common symptom of lupus.
There are multiple types of lupus diagnoses.

34

Treatment can cure lupus.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

False

False
True
True
False
True
False
False
True
True
True
False
False
True
True
True
True
True
False
True
True
False
False
False
True
False
False
False
True
False
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Figure 1: LKQ- draft Total Percentage (out of 100%, 38 items)

LKQ Scores Sample #1 (N=366)
0%

0%

0-9% (N=204)

4% 3%

10-19% (N=26)

6%

20-29% (N=17)

6%

30-39% (N=19)
6%

40-49% (N=19)

5%

50-59% (N=21)
62%
8%

60-69% (N=12)
70-79% (N=9)
80-89% (N=1)
90-100% (N=2)
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Figure 2: LKQ- revised Total Percentage (out of 100%, 34 items)

LKQ Scores Sample #2 (N=188)
2%

1%

8%

0-9% (N=24)
10-19% (N=15)

13%

20-29% (N=23)
8%

12%

30-39% (N=17)
40-49% (N=30)

12%

50-59% (N=35)
60-69% (N=23)

19%
9%

70-79% (N=16)
80-89% (N=3)

16%

90-100% (N=2)
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